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Pressure overload-induced heart failure 
Currently, heart failure is one of the leading causes of death worldwide, affecting around 
26 million people1. Aortic stenosis and systemic arterial hypertension, each resulting in 
cardiac pressure overload, belong to the most-frequent cardiovascular diseases and major 
risk factors of heart failure2. There is still no effective therapy to cure the pressure-
overloaded heart and in contrast to other cardiovascular diseases, its incidence, prevalence, 
and economic costs are steadily increasing. Currently, over 1.13 billion people suffer from 
hypertension worldwide, a number that has nearly doubled since 1975 and is still on the 
rise3. Furthermore, hypertension is the underlying cause of 45% of all deaths caused by 
cardiac problems4. Also the incidence of aortic stenosis, the most serious global valve 
disease problem, reaches epidemic proportions. With demographic aging of the global 
population the incidence of pressure overload-induced heart failure is expected to increase 
even further, thereby stressing the urgent need for effective medical therapy.  
Pressure overload is a condition in which the cardiac muscle has to contract while 
experiencing an excessive afterload. In response to this increased afterload, the heart will 
increase its muscle mass, leading to the development of cardiac hypertrophy. It has initially 
been thought that this hypertrophic response functioned as a compensatory mechanism to 
help maintain cardiac output, but current literature challenges this dogma by suggesting 
that hypertrophy itself is a pathological (non-compensatory) response5. Either way, this 
cardiac hypertrophy will ultimately become maladaptive and the heart will start to fail6, 7. It 
has been proposed that altered cardiac energy metabolism contributes to the development 
of cardiac hypertrophy and finally also to that of heart failure8, 9.  
 
Cardiac metabolism in the healthy heart 
The heart is an organ that pumps blood throughout the entire body via the vascular system, 
providing oxygen and nutrients to the peripheral tissues and thereby warranting proper 
function of these tissues. Optimal cardiac pump function is required to maintain this 
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sufficient supply of oxygen and nutrients to the periphery10, 11. Maintenance of pump 
function is inevitably linked to the availability of energy in the form of ATP. This ATP can be 
derived from a high-energy-phosphate pool (phosphocreatine; PCr), but in the heart this 
pool is relatively small and can be exhausted within a few seconds12, 13. Therefore, the 
majority of ATP is generated continuously in the mitochondria via the utilization of several 
classes of cardiac substrates, including long chain fatty acids, glucose, amino acids, ketone 
bodies and lactate.  
In the healthy heart, fatty acids are the predominant substrate and account for 
approximately 60–70% of energy provision, whereas 10–40% of the energy is generated by 
the utilization of glucose. Ketone body, amino acid and lactate oxidation cover the 
remaining contribution12, 14. Under a variety of physiological conditions the healthy heart is 
metabolically flexible, which confers the advantage of adequately supplying ATP for 
continual cardiac contraction. However, when exposed to pathophysiological stressors, the 
heart loses its ability to switch between substrates and this will eventually lead to 
contractile failure15. An example of such pathophysiological stressor is “pressure overload”.  
 
Cardiac metabolism in the pressure-overloaded heart 
At an early stage, chronic pressure overload-induced heart failure is characterized by 
deranged myocardial fuel metabolism, shifting from predominant mitochondrial oxidation 
of fatty acids towards almost complete reliance on glucose uptake and glycolysis (Figure 
1)16, 17. This shift is accompanied by the re-activation of the “fetal gene program”, which is 
characterized by an increase in the expression of fetal genes such as α-myosin heavy chain 
(α-MHC), β-myosin heavy chain (β-MHC), sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA2a), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and glucose 
transporter 1 (GLUT1), and the development of cardiac hypertrophy18, 19. It has been 
suggested that these changes in gene expression are an adaptive cardioprotective process, 
possibly triggered by glucose-derived metabolic signals18. Interestingly, the significant 
increase in glucose uptake in pressure overload is not concomitant with a parallel increase 
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in glucose oxidation, leading to uncoupling of glycolysis from glucose oxidation20-22. At this 
stage, anaplerosis is upregulated to replenish the tricarboxcylic acid cycle (TCA) flux23, but 
is rather inefficient in terms of glucose metabolism. Matching the rate of glycolysis and 
glucose oxidation could, therefore, be key to improve contractile function. Regarding fatty 
acid metabolism, fatty acid oxidation was clearly diminished in animals subjected to 
pressure overload24, 25, but there is no clear consensus with respect to alterations in the rate 
of fatty acid uptake in the pressure-overloaded heart16, 26. More research into this particular 
area is therefore required.  
While these early changes induced by pressure overload generally are regarded as 
cardioprotective, and result in maintenance of contractile function, at a later stage during 
persistent pressure overload the energy supply often can no longer match energy demand, 
eventually leading to severe left ventricular dysfunction, and consequently heart failure. 
When the heart progresses towards this severe-stage or end-stage of heart failure it is 
characterized by (i) decreased fatty acid uptake and utilization, (ii) insulin resistance, and 
(iii) impaired myocardial glucose uptake and oxidation24, 27-30. This overall decrease in energy 
metabolism leads to an energy depleted state of the heart, accompanied with ventricular 
dilatation, in which the heart is no longer able to contract accordingly (Figure 1).  
 
Figure 1. Schematic overview of metabolic alterations during the development of pressure overload-induced heart 
failure. 
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Protein turnover in the pressure-overloaded heart 
Protein turnover represents the balance between protein synthesis and breakdown. In the 
normal heart, protein turnover helps maintain the protein pool in homeostasis through 
continual synthesis and degradation31. When the heart encounters an environment of 
pressure overload, this protein turnover becomes disturbed, leading to the development of 
cardiac hypertrophy at an early stage of heart failure. Cardiac hypertrophy is characterized 
by a net increase in protein synthesis32. It has been proposed that the activation of a key 
regulatory protein in protein synthesis, the protein kinase mTOR (mammalian or 
mechanistic Target of Rapamycin), by glycolytic intermediates, plays an important role in 
the development of cardiac hypertrophy9. Additionally, activation of the canonical protein 
kinase D1 (PKD1)-pathway has also been implicated in the structural remodeling of the 
heart. One of the key downstream substrates of PKD1 is histone deacetylase-5 (HDAC5), a 
member of the HDAC family that negatively regulates the acetylation status of nucleosomal 
histones. HDAC5 is able to bind to the transcription factor myocyte enhancer factor-2 
(MEF2), thereby repressing the transcription of a number of fetal genes33, 34. 
Phosphorylation of HDAC5 by PKD1 activation results in disassociation from MEF2, and 
might therefore be an important contributor to the development of cardiac hypertrophy. 
During the progression of heart failure towards a severe-stage, a net increase in protein 
synthesis exceeds the folding capacity of the endoplasmic reticulum (ER), thereby inducing 
ER-stress and the accumulation of damaged and misfolded proteins35, 36. To enhance the 
clearance of those large amounts of misfolded proteins, the autophagic flux is 
upregulated37. Moreover, prolonged ER-stress also triggers the activation of pro-apoptotic 
signaling cascades that even further contribute to cardiomyocyte dysfunction38 and finally 
results in severe ventricular dilatation and cell death. 
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Potency for therapeutic approaches that focus on restoring the metabolic 
balance 
Recently, several studies have shown that the metabolic changes in glucose uptake and the 
mitochondrial energy deficits during the development of pressure overload-induced heart 
failure precede structural and functional changes in the heart9, 24, 39-41. This suggests that 
metabolic targeting aimed at restoring mitochondrial energy provision could prevent 
profound structural and functional abnormalities in pressure overload-induced heart 
failure, which would make metabolic interventions a potential therapeutic approach. 
Further support that targeting metabolism (so as to obtain the metabolic profile as 
observed in the healthy heart) is an promising strategy, is provided by an in vivo study with 
protein kinase D1 (PKD1)-overexpressed mice42. On a normal chow diet, these mice showed 
a metabolic shift towards predominant cardiac glucose utilization, while developing cardiac 
hypertrophy and ventricular dilation. However, when these mice were subjected to a high 
fat-diet (forcing them towards increased fatty acid utilization), these abnormal metabolic, 
structural and functional parameters were no longer apparent. A similar protective effect 
on cardiac function was observed in mice with a cardiac-specific deletion of acetyl-CoA via 
acetyl-CoA carboxylase (ACC2). These mice showed increased fatty acid oxidation, and the 
deletion of ACC2 prevented metabolic reprogramming and sustained myocardial energetics 
(PCr/ATP ratios) and function in a model of pressure overload43.  
 
Outline of this thesis 
Given the emerging crucial role of metabolic changes during the development of pressure 
overload-induced heart failure and the promising outlook of metabolic interventions as 
effective strategy to prevent or perhaps rescue the failing heart, in this thesis we aimed at 
developing experimental models for pressure overload-induced heart failure to enable the 
further study of the underlying molecular mechanisms as well as the study of various 
metabolic interventions.  
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To study these aims, in this thesis emphasis was put on mapping metabolic changes during 
the development of pressure overload-induced heart failure in both in vitro and in vivo 
models in an attempt to unravel the mechanism behind this specific type of heart failure. In 
chapter 2, the current state of knowledge regarding substrate metabolism during the 
development of pressure overload-induced heart failure has been summarized. Because 
substrate transporters form a main rate governing step in metabolic substrate utilization, 
they may offer good targets for therapeutic treatment of pressure overload-induced heart 
failure. Specifically, in this chapter we focused on expression levels and subcellular 
distribution of the substrate transporters (including those of both predominant and 
alternative substrates). Chapter 3 is devoted to the generation of an in vitro model to mimic 
pressure overload-induced heart failure. This model allowed us to obtain a better insight 
into the molecular mechanisms behind pressure overload-induced heart failure and to 
search for new targets to prevent pressure overload-induced heart failure. In chapter 4, we 
additionally aimed to set-up an in vivo model of slowly progressing pressure overload to 
study metabolic alterations in relation to changes in protein synthesis during the 
development of pressure overload-induced heart failure. For this model rats were subjected 
to transverse aortic constriction (TAC) surgery.  
To test whether stem cell-derived cardiomyocytes could function as a relevant human tool 
to study pressure overload-induced heart failure, we examined the metabolic properties of 
human stem cells and their derived cardiomyocytes. Because of the amply available 
expertise with respect to in vitro models of insulin resistance in our research group, for 
practical reasons we first tested these human-derived cardiomyocytes in a model of insulin 
resistance. Results of this study are presented in chapter 5. Based on these first data, future 
research may focus on the implementation of stem cell-derived cardiomyocytes in a model 
of pressure overload-induced heart failure, allowing us to make the translation of the 
findings presented in chapters 3 and 4 towards a human setting. Finally, in chapter 6 a 
summary of the main results presented in this thesis is given, and based on these results 
new insights are discussed in a broader perspective.  
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Abstract  
Cardiac pressure overload (PO), such as caused by aortic stenosis and systemic 
hypertension, commonly results in cardiac hypertrophy and may lead to the development 
of heart failure. PO-induced heart failure is among the leading causes of death worldwide, 
but its pathological origin remains poorly understood. Metabolic alterations are proposed 
to be an important contributor to PO-induced cardiac hypertrophy and failure. While the 
healthy adult heart mainly uses long-chain fatty acids (FAs) and glucose as substrates for 
energy metabolism and to a lesser extent alternative substrates, i.e. lactate, ketone bodies, 
and amino acids (AAs), the pressure-overloaded heart is characterized by a shift in energy 
metabolism towards a greater reliance on glycolysis and alternative substrates. A key-
governing kinetic step of both FA and glucose fluxes is at the level of their substrate-specific 
membrane transporters. The relative presence of these transporters in the sarcolemma 
determines the cardiac substrate preference. Whether the cardiac utilization of alternative 
substrates is also governed by membrane transporters is not yet known. In this review, we 
discuss current insight into the role of membrane substrate transporters in the metabolic 
alterations occurring in the pressure-overloaded heart. Given the increasing evidence of a 
role for alternative substrates in these metabolic alterations, there is an urgent need to 
disclose the key-governing kinetic steps in their utilization as well. Taken together, 
membrane substrate transporters emerge as novel targets for metabolic interventions to 
prevent or treat PO-induced heart failure. 
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1. Introduction 
Heart failure remains the leading cause of death worldwide.1 It is defined by clinical 
symptoms such as dyspnoea, fatigue, and ankle swelling.2,3 Before these symptoms become 
apparent, the patient’s heart often undergoes asymptomatic structural or functional 
abnormalities (left ventricular dysfunction).2 Recognition of these changes is important as 
they are related to poor outcomes. There are many underlying pathologies that can lead to 
heart failure. Aortic stenosis and systemic arterial hypertension, each resulting in cardiac 
pressure overload (PO), belong to the most-frequent cardiovascular diseases and major risk 
factors of heart failure.4 Upon aortic stenosis, the blood flow from the left ventricle to the 
aorta is restricted leading to an increased resistance to systolic ejection. During 
hypertension, the increased systemic blood pressure imposes an elevated afterload to the 
left ventricle. In response to the increased afterload and increased left ventricular wall 
stress in aortic stenosis or hypertension, the heart increases its muscle mass (hypertrophy). 
Where this hypertrophic response has initially been thought to compensate and help 
maintain an adequate cardiac output, current literature challenges this dogma by 
suggesting that the hypertrophy itself is a pathological (non-compensatory) response.5 
Either way, in the long term this concentric hypertrophy may become maladaptive and will 
lead to diastolic dysfunction.6 Left ventricular hypertrophy occurs in about 10–15% of the 
general population,7 in 85% of aortic stenosis patients8 and in 40% of hypertensive 
patients.9 Although several antihypertensive drugs exist, not all are equally effective. The 
underlying mechanism of this transition of PO towards cardiac hypertrophy and failure 
(from now on referred to as the pressure-overloaded heart) remains unknown. It has been 
proposed that in the pressure-overloaded heart altered cardiac energy metabolism—in 
particular substrate preference—is an important (early) contributor to the development of 
cardiac hypertrophy and subsequent failure and, therefore, might function as a suitable 
treatment target.10 
The human adult heart is able to utilize a wide variety of substrates for energy provision, 
i.e. fatty acids (FAs), carbohydrates, and to lesser extent lactate, ketone bodies, and amino 
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acids (AAs). Under physiological conditions, the heart mainly oxidizes FAs and glucose and 
is metabolically flexible, i.e. is able to rapidly shift between these substrates upon changing 
conditions, such as availability of substrates, workload, and hormonal influences.11 
However, when chronically exposed to pathophysiological stressors, the heart loses its 
ability to switch between substrates and this may eventually lead to contractile failure. For 
instance, the pathophysiological condition of chronic PO is characterized by a shift away 
from the predominant utilization of FAs towards increased glycolysis.12,13 It is suggested that 
this initially adaptive shift eventually becomes maladaptive and then contributes to the 
development of heart failure. 
Substrate utilization can be determined at the level of substrate availability, cellular 
substrate uptake, and trapping, conversion into metabolites that can be taken up by 
mitochondria, and subsequent mitochondrial oxidation. Because of rapid conversion of 
substrates upon cellular entry (at least for the main substrates glucose and FAs) the 
transsarcolemmal uptake process is unidirectional, thereby presents itself as a key 
regulatory step. Key regulators of myocardial FA and glucose uptake are their substrate-
specific transporters expressed on the cellular surface of cardiomyocytes, which therefore, 
present the rate-controlling site for cardiac FA and glucose fluxes.14 FA and glucose 
transporters (GLUTs) have been studied comprehensively, indicating an important role for 
the FA transporter, CD36 (officially known as SR-B2), and the GLUTs, GLUT1 and GLUT4, in 
facilitating FA and glucose uptake into the heart, respectively.15,16 
Recent data also implies an important role for the alternative substrates in the pressure-
overloaded heart. Up-regulated key enzymes in the ketone oxidation pathways, and 
catabolism of branched chain amino acids (BCAAs) have been associated with cardiac 
hypertrophy and failure.17,18 Interestingly, the transport of these alternative substrates 
across the sarcolemma of cardiomyocytes may also be a key factor in regulating their 
utilization.17,19 The role of lactate, ketone bodies, and AAs and their specific transporters 
remains, however, underexplored. 
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This review will summarize the current state of knowledge regarding the various cardiac 
transmembrane substrate transporters of both the main and the alternative substrates, and 
their specific functioning in the healthy heart and in the pressure-overloaded heart during 
the development of heart failure. To sum up, substrate-specific transporters at the 
cardiomyocyte sarcolemma are a promising target for metabolic intervention strategies to 
prevent or regress the development of PO-induced heart failure or to rescue the pressure-
overloaded heart. 
2. Substrate transporters in the healthy heart 
2.1 Glucose transporters 
The hydrophilic properties of the glucose molecule limit its diffusion through the lipid 
bilayer of the sarcolemma. Therefore, glucose transport across the sarcolemma is facilitated 
by glucose-specific transporters. In the heart glucose functions as a substrate for energy 
provision, but also plays an important role in cell signalling and biomolecule synthesis.20,21 
The most abundant glucose transporters (GLUTs) expressed in the heart are the GLUT 
family, particularly the Class I isoforms GLUT1 and GLUT4 (Table 1). These passive 
uniporters facilitate glucose transport via diffusion based on the glucose concentration 
gradient. In the adult heart, GLUT4 is expressed to a subsequently higher extent than 
GLUT1.22 Other members of the GLUT family (GLUT3, GLUT8, GLUT10, GLUT11, and GLUT12) 
are also present in the heart, but to a lesser extent (Table 1). While these additional GLUTs 
are involved in cardiac foetal development and the transport of other hexoses, their 
involvement in glucose uptake in the adult heart remains unknown.16,20,21,23 Next to the 
GLUTs, six members of the family of sodium-glucose linked transporters (SGLT) are present 
in the heart, of which SGLT1 and SGLT2 are the most abundant (Table 1).21 This family, 
consisting of 12 isoforms, uses the sodium gradient to actively transport glucose across the 
plasma membrane into the cell. Studies with SGLT1−/− and SGLT2−/− mice do not show 
alterations in cardiac glucose uptake.24 These data seem at odds with the well-known 
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beneficial effects of SGLT inhibitors on cardiac function in human patients with various 
cardiac metabolic diseases.25 However, it has also been proposed that the effects of SGLT 
inhibitors on the heart are indirect, i.e. via haemodynamic improvements.25 Hence, it is 
concluded that SGLTs are of minor importance in regulation of cardiac glucose uptake.  
The relative contribution of GLUT1 and GLUT4 transporters to the regulation of glucose 
uptake is not only dependent on differences in their expression but also determined by 
differences in subcellular localization. GLUT1 is constitutively present at the cellular 
membrane to mediate basal (non-stimulated) glucose uptake. GLUT4 on the other hand is 
retained in endosomal compartments and is able to quickly translocate towards the 
sarcolemma upon various physiological and pharmacological stimuli.16 Short-term 
regulation involves vesicular GLUT4 translocation towards the cell membrane mediated by 
the phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)–protein kinase B (PKB/Akt) 
insulin signalling pathway, or by the AMP-activated protein kinase (AMPK) contraction-
induced signalling pathway (Table 1). Key points of convergence of these signalling 
pathways are the Rab GTPase activating proteins AS160 (also known as TBC1D4) (Figure 1) 
and its homologue TBC1D1. Phosphorylation of both Rab GTPase activating proteins 
releases the break on the activity of a set of Rab GTPases (Rab8a, Rab10, Rab11, and Rab14). 
Activation of these Rabs drives the unidirectionality and specificity of trafficking, which is 
additionally supported by a variety of Rab effector proteins.26 Like any other subcellular 
vesicular trafficking process, GLUT4 translocation obeys to the principles of the SNARE 
theory in which pairs of cognate v-SNAREs at the donor compartment and t-SNAREs at the 
acceptor compartment confer the specificity of vesicular trafficking. VAMP2 is the v-SNARE 
for insulin-stimulated GLUT4 translocation in the heart, and VAMP3 mediates contraction-
stimulated GLUT4 translocation.27 Long-term regulation of glucose transport involves 
alterations in activity of transcription factors and is associated with alterations in gene 
expression, such as the hypertrophic transcription factor myocyte enhancer factor-2 (MEF2) 
which is a central regulator of GLUT4 expression.28,29 GLUT1 expression in the heart can be 
regulated by the transcription factors activator protein 1 (AP1) and the hypoxia-induced 
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factor-1α (HIF-1α).29–31 The subcellular distribution of additional GLUTs in the heart and the 
mechanisms involved in short-/long-term regulation of their expression levels remain to be 
elucidated. Additionally, there are some indications that GLUT transporters are able to 
enhance substrate uptake via augmented intrinsic activity of GLUT transporters 
independent of transporter recruitment towards the sarcolemma.32 
 
Figure 1. Schematic presentation of cardiac specific membrane substrate transporters and their distribution (endosomes vs. 
sarcolemma) within cardiomyocytes. GLUT 1 and GLUT4 are the predominant glucose transporters in the heart. Under basal 
conditions GLUT1 is constitutively present at the sarcolemma, whereas GLUT4 is mainly located in endosomal compartments where 
it is able to rapidly translocate towards the sarcolemma upon hormonal (insulin) or contractile (AMP/ATP ratio) stimuli, both 
involving phosphorylation of AS160 and/or TBC1D1 (not indicated; both Rab GTPase activating proteins). Whether GLUT1 also has 
translocation ability under specific stimulation conditions remains to be elucidated. The predominant LCFA transporter in the heart 
is CD36. Similar to GLUT4, CD36 is situated in endosomal compartments and is able to translocate towards the sarcolemma upon 
hormonal or contractile stimuli. For lactate and ketone body transport MCT1 and MCT4 transporters appear most abundant in the 
heart. MCT1 is primarily localized on the sarcolemma, while the exact localization of MCT4 and the translocation ability of both 
transporters are unknown. For amino acid transport, three types of bidirectional L-type transporter systems (Asc-1, LAT2, and 
y<sup>+</sup>LAT2) and cationic amino acid transporters (CATs) have been identified in the heart, but their subcellular distribution 
and their translocation ability remain to be investigated. The question mark (?) indicates that it is unknown if these transporters 
translocate between endosomes and sarcolemma. 
Chapter 2  | 
24 
 
2.2 FA transporters 
Short-chain FAs and medium-chain FAs both combine favourable hydrophilic properties 
with relatively good lipophilic properties so that these substrates do not need any carrier or 
transporter to be taken up into cells. For comparison, long-chain FAs (from now on referred 
to as FAs) have increased lipophilic properties and much lower aqueous solubility. To 
increase their aqueous solubility, FAs require binding-proteins, such as extracellularly 
available albumin and intracellular cytoplasmic fatty acid binding protein (FABPc).33 Related 
to their lipophilic properties, FAs readily partition into biological membranes, but their 
desorption from the lipid bilayer into the cytoplasm is limited. To overcome this barrier, a 
protein-mediated mechanism is required to direct the FAs into metabolic pathways. In this 
respect, several membrane-associated FA transporters, including plasma membrane fatty 
acid-binding protein (FABPpm), integral fatty acid transporter proteins 1–6 (FATP 1–6), and 
fatty acid translocase (FAT/CD36) have been identified in the heart (Table 1).15,34 FA uptake 
by these transporters is driven by a steep FA concentration gradient across the sarcolemma 
(high extracellular; low intracellular). In the heart FAs play a major metabolic role as energy 
source but also function as cellular signalling molecules and as incorporated components of 
the phospholipid bilayer in cellular membranes.33 
CD36 is currently known as the predominant membrane protein facilitating cardiac FA 
transport.15 Studies with CD36-specific inhibitors as well as in CD36 knockout mice have 
convincingly shown that CD36 quantitatively contributes to >70% of cardiac FA uptake 
(depending on the metabolic status).35,36 Within the FATP family, FATP1 and FATP6 are the 
main expressed isoforms in cardiomyocytes, but their role might be limited to uptake of 
very-long-chain FAs. In contrast to CD36, these cardiac FATPs are exclusively targeted to 
specific areas of the sarcolemma.37 Moreover, CD36 seems to act synergistically with 
FABPpm, as FA uptake is inhibited in a non-additive manner by CD36-specific inhibitors and 
by anti-FABPpm antibodies (Table 1, Figure 1).37,38 Short-term regulation of FA uptake is 
mediated by hormonal (insulin) and mechanical stimuli (increased AMPK-induced 
contraction signalling), which trigger translocation of CD36 from intracellular storage 
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compartments (endosomes) to the sarcolemma via membrane vesicles within minutes in a 
manner analogous to short-term regulation of GLUT4 translocation (Table 1, Figure 1). This 
latter analogy extends to the v-SNAREs involved with VAMP2 and VAMP3 mediating insulin 
and contraction-induced CD36 translocation, respectively. In contrast, VAMP4 is specifically 
involved in CD36 translocation, and not in that of GLUT4.27 Furthermore, all Rab members 
mediating GLUT4 translocation are also involved in CD36 translocation,39 but at least one of 
the Rab effector proteins, i.e. Rab 11 effector Rip11, appears specific for the CD36 trafficking 
machinery. Long-term regulation of cardiac FA uptake involves alterations in gene 
expression, such as oestrogen-related receptor α,40 key peroxisome proliferator-activated 
receptor-α (PPARα), and its co-activator PPAR-gamma co-activator-1α.15 
2.3 Lactate and ketone body transporters 
The role of lactate and ketone bodies in metabolically active organs has been understudied. 
For a long time, lactate was considered a metabolic waste product, derived from glycolysis. 
However, in recent decades it became clear that lactate also plays a small but marked role 
as metabolite when energy demands are high.41,42 Ketone bodies are synthesized in the liver 
from where they are transported towards extra-hepatic tissues for oxidation (acetoacetate, 
AcAc; β-hydroxybutyrate, β-OHB) or are excreted by exhalation (acetone). They can serve 
as circulating energy source for tissues, like brain, heart, and skeletal muscle in times of 
fasting and prolonged exercise.43,44 
In the human body, lactate transport across the sarcolemma is facilitated by a group of H+-
coupled or Na+-coupled monocarboxylate transporters (MCTs). Transmembrane transport 
of ketone bodies is facilitated by this same group of transporters.45,46 Currently, there are 
four well-known H+-coupled MCT (MCT1, MCT2, MCT3, and MCT4) with distinct affinities 
for specific substrates and different expression levels between tissues.42,47 While the above-
mentioned transporters are all expressed in the heart, the MCT1 and MCT4 proteins appear 
most abundant, although there are species differences (Table 1, Figure 1). This expression 
pattern indicates a potentially bigger role for MCT1 and MCT4 in cardiac lactate and ketone 
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body uptake and/or efflux compared to other transporters.48,49 Sarcolemmal expression, 
transporter activity, delivery of transporters from the endoplasmic reticulum to the cellular 
membrane, and stability of these transporters are regulated by basigin (CD147) and embigin 
(gp70) which function as glycoproteins, anchoring MCTs (particularly MCT1 and MCT4) to 
the sarcolemma.50–52 Myocardial MCT1 is primarily localized on the sarcolemma and rarely 
associated with internal membrane compartments of cardiomyocytes, implying that there 
is a constitutive functional expression of this transporter.53 This also would suggest that 
enhanced lactate or ketone body fluxes under physiological or pathological conditions are 
mainly due to altered substrate gradients rather than changes in MCT translocation to the 
sarcolemma. At long term, MCT expression can be regulated by a variety of stimuli. Under 
hypoxic conditions, MCT4 expression can be up-regulated through a HIF-1α-dependent 
mechanism. HIF-1α is able to bind to two hypoxia response elements which are present in 
the MCT4 promotor, but absent in MCT1 and MCT2 promotors.49,54 Moreover, exercise 
enhances MCT1 expression in the heart and skeletal muscle.47,48 Although the exact 
mechanism still remains to be elucidated, there might be a role for AMPK, which stimulates 
the MCT1 promotor upon activation. An additional mechanism is elevated Ca2+ levels that 
are able to activate the MCT1 promotor via the transcriptional factor nuclear factor of 
activated T-cells. 
2.4 Amino acid transporters 
AAs are essential building blocks for proteins, but they also play an important role in cell 
signalling and as metabolite precursors for a wide variety of cells. In mammalian cells, a 
broad range of AA transporter systems (System A, ASC, and L) is present to facilitate the 
movement across the cellular plasma membrane. System A and system ASC transporters 
mainly facilitate active influx of short-chain AAs across their concentration gradient, 
whereas the bidirectional L-type transport system utilizes the intracellular AA pool, 
generated by the A and ASC transporter systems, to actively facilitate the influx of large, 
neutral, branched-chain, or aromatic AAs.55,56 These transporter systems can be further 
classified into distinct categories based on their substrate specificity, transport 
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mechanisms, and regulatory properties (reviewed by Hyde et al.56). For the L-type 
transporter system-specific membrane glycoproteins (rBAT or 4F2hc) are required to form 
a functional transporter system.56,57 
Yet, the exact transport mechanism of AAs into the heart remains poorly understood. There 
are some indications for a pivotal role for the bidirectional L-type transporter systems.18,58 
At least three types of cardiac L-type amino acid transporters are identified (y+LAT2, LAT2, 
and Acs-1). Whereas y+LAT2 requires Na+, LAT2 facilitates the exchange of AAs in a Na+-
independent manner.56,57 Na+-independent transport of glycine, L-alanine, L-serine, L-
threonine, L-cysteine, α-aminoisobutyric acid, and β-alanine is mainly mediated by alanine-
serine-cysteine transporter 1 (Asc-1),59 whereas y+LAT2 preferentially mediates the efflux 
of L-arginine in exchange of L-glutamine plus Na+.60 In addition to the L-type transporter 
systems, some studies report the presence of the cationic amino acid transporters (CATs) in 
cardiomyocyteks.61,62 Interestingly, mRNA expression of CAT1 and CAT2B is enhanced by 
insulin and cytokines, thereby increasing L-arginine uptake into the heart (Table 1, 
Figure 1).61 The latter indicates that insulin and cytokines have the potential to regulate AA 
transport. Insulin-induced AA transport has previously been shown in skeletal muscle, 
whereby the insulin action includes translocation of the System A transporter 2 (SAT2) from 
an intracellular storage pool towards the sarcolemma.67 However, whether the cardiac LATs 
and CATs also can be recruited towards the cellular membrane via a translocation process, 
and whether this can be regulated by specific hormonal stimulation, remains to be studied. 
3. The role of substrate transporters in the pressure-overloaded heart 
Chronic PO can result in the development of cardiac hypertrophy and eventually heart 
failure. The transition from a healthy towards a hypertrophic and finally failing heart is 
accompanied by alterations in cardiac energy metabolism. Whereas the healthy heart 
predominantly utilizes FAs (60–90%) and glucose (10–30%) as substrates for oxidative 
energy provision and to a lesser extent lactate, ketone bodies, and AAs, the pressure-
overloaded heart is characterized by a switch from FAs towards glycolysis.10 This shift 
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towards glycolytic metabolism is initially thought to be an adaptive response to gain higher 
oxygen efficiency (more ATP generation per consumed oxygen molecule) (Figure 2).68 There 
is, however, no conclusive evidence that a shift towards glucose utilization or towards 
utilization of alternative substrates, such as ketone bodies which are more oxygen-efficient 
than FAs is beneficial to cardiac function. Studies with epinephrine69,70 suggest that the 
advantage of a switch to preferred glucose utilization relates to a higher ATP flux through 
creatine kinase, rather than an increased ATP content or increased PCr/ATP ratio. 
Interestingly, a reduction in ATP flux through creatine kinase was seen in patients71,72 and 
animal models73,74 with PO-induced hypertrophy and failure. A causal relationship between 
altered energy metabolism and contractile dysfunction has however not been proven so 
far.  
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Figure 2. Proposed mechanism by which alterations in sarcolemmal substrate transporter presence—thereby alterations in 
substrate uptake—contribute to the development of PO. (A) In the healthy heart, the preference for FA utilization is driven by 
substrate-specific transporter content at the sarcolemma (a key-governing kinetic step in cellular FA utilization). Transporter-
mediated influx of FAs is high, whereas the influx of glucose, lactate, ketone bodies, and amino acids, via their specific transporters, 
is relatively low. (B) In the pressure-overloaded heart, sarcolemmal presence of GLUT1 and GLUT4 increases, whereas sarcolemmal 
CD36 presence decreases. This increase in sarcolemmal glucose transporters (thereby enhanced glucose uptake/glycolysis) triggers 
hypertrophic growth.<sup>5</sup> Additionally, the heart increases the uptake of lactate, ketone bodies, and amino acids, either 
by enhancing sarcolemmal presence of their specific transporters or by increased transmembrane gradients, to serve as alternative 
substrates for mitochondrial energy provision. Thickness of the black arrows indicates the relative rate of substrate influx. Red 
arrows indicate either an up-regulation (↑) or down-regulation (↓) of sarcolemmal substrate-specific transporters under the 
condition of PO. AAs, amino acids; ADP, adenosine diphosphate; BCAAs, branched-chain amino acids; BCKAs, branched-chain keto 
acids; KAs, keto acids; TCA, tricarboxylic acid; β-ox, β-oxidation. 
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On the other hand, the increased glycolytic flux in the pressure-overloaded heart does not 
seem to be matched by a commensurate increase in glucose oxidation, leading to inefficient 
glucose metabolism.75–77 The tricarboxylic acid (TCA) cycle was shown to remain normal in 
the pressure-overloaded heart despite decreased FA oxidation, due to increased 
anaplerosis of glycolysis-derived pyruvate.78 Anaplerosis is energetically less efficient than 
pyruvate oxidation because it bypasses oxidative decarboxylation and other ATP-generating 
steps of the TCA cycle.75–77 Matching the rate of glycolysis and glucose oxidation, rather than 
increasing glucose oxidation per se could, therefore, be key in improve contractile function. 
Such matching could be achieved by regulating glucose uptake via the GLUTs, thereby 
restoring the maladaptive increased flux towards glycolysis under pathological conditions. 
Recently, more studies point towards an important role for lactate, ketone bodies and AAs 
as alternative energy source in the pressure-overloaded heart (Figure 2).17,18 Below, the 
changes in utilization that occur in the pressure-overloaded heart for each of the substrates 
are discussed with emphasis on the role of substrate transporters (summarized in Table 2, 
taking into account the type, stage, and severity of heart failure). Where relevant, other 
heart diseases related to PO are included. Not for every substrate sufficient information 
about the respective transporter was present, so that in those instances we focused on 
changes in substrate concentrations and in substrate metabolism. Of note, the majority of 
data on substrate transporters in the pressure-overloaded heart has been generated from 
animal studies, whereas limited research has been conducted in humans. Though, one study 
in patients with aortic stenosis showed that the development of cardiac hypertrophy is 
correlated positively with total cardiac GLUT4 protein levels and negatively with total CD36 
protein levels.79 
3.1 Glucose transporters 
On the level of GLUTs, an up-regulation of GLUT1 mRNA and protein has been observed in 
cardiomyocytes in vitro-stimulated with hypertrophic agents.80 Moreover, two studies81,82 
in spontaneous hypertensive rats, a naturally occurring model of PO, provide evidence for 
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repressed GLUT4 expression, in one case concomitantly with increased GLUT1 expression. 
These changes can be explained by reactivation of the foetal gene programme during the 
development of cardiac hypertrophy. It has been reported that hypertrophy is accompanied 
by reduced PPARα levels.83 Inactivation of PPARα is associated with increased expression of 
foetal-like-genes,83 such as GLUT-1. Additionally, it has been reported that cardiac 
hypertrophy is accompanied by increased expression of HIF-1α, which is known to be an 
important transcription factor involved in GLUT1 transcription.30 These observations are 
unfortunately only based on total mRNA and protein levels, whereas it is to be expected 
that intrinsic activity of these transporters as well as their distribution between intracellular 
storage and cell surface localization is additionally relevant in terms of substrate 
utilization.26,32,84 A study in rats that specifically distinguished between total GLUT protein 
expression and sarcolemmal distribution showed increased sarcolemmal GLUT1 and GLUT4 
protein contents after ascending aortic constriction, whereas total GLUT1 protein 
expression was increased but total GLUT4 protein expression decreased.85 These findings 
are in line with in vitro studies with isolated cardiomyocytes where increased glucose 
uptake was accompanied with an increase in GLUT4 translocation to the sarcolemma.86,87 
Increased GLUT4 translocation in the heart exposed to hypertension could be due to 
activation of protein kinase-D1 (PKD1) via signalling initiated by the hypertensive hormones 
angiotensin-II and endothelin-I.88 PKD1 stimulates GLUT4 translocation via a yet unknown 
pathway involving endosomal lipid kinases.89 On the other hand, both hormones are 
reported to inhibit upstream insulin signalling.90 Hence, increased basal GLUT4 
translocation may be accompanied by decreased insulin-induced GLUT4 translocation. 
Controversial to these findings, reduced GLUT4 expression at the sarcolemma concurrently 
with increased GLUT4 expression in the cytoplasm has been reported in mice subjected to 
transverse aortic constriction (TAC).91 These apparently discrepant findings remain 
unexplained. 
To further investigate the role of specific GLUTs with respect to changed glucose uptake in 
the pressure-overloaded heart, several studies explored the effect of GLUT overexpression 
Chapter 2  | 
32 
 
and of knockout models. Based on the above findings, the possibility exists that the increase 
in GLUT1 expression observed in PO could be cardioprotective. This theory is supported by 
studies with cardiac-specific short-term and life-long overexpression of GLUT1, where 
mitochondrial function is preserved and adverse pathological remodelling is prevented in 
mice with aortic constriction.92,93 Interestingly, loss of GLUT1 did not accelerate the 
transition from compensated hypertrophy to heart failure when subjected to TAC,94 
suggesting that GLUT1 is not the most critical player in cardiac adaptations in the pressure-
overloaded heart. On the other hand, mice with cardiac-specific GLUT4 deletion developed 
significantly greater hypertrophy and more severe contractile dysfunction after TAC 
compared to their wild-type littermates.95 This latter study suggests that GLUT4 may be 
required (and therefore more important than GLUT1) for maintenance of cardiac structure 
and function in response to PO. 
Differences in outcome between studies could be attributed to choice of species, specific 
models used to study PO, time after initiation of PO, and the specificity of experimental 
read-out parameters, so caution is probably required while drawing conclusions. 
Specifically, it has been suggested that changes on the level of transporters may depend on 
the stage of the disease. For example, in a model of myocardial infarction (MI) the transition 
from compensated hypertrophy to heart failure was associated with an up-regulation of 
GLUT1,96 whereas a down-regulation of GLUT1 and GLUT4 has been observed in end-stage 
failing human hearts.97 Discrepancies between in vitro and in vivo studies could also be 
attributed to non-cardiomyocyte cell-types contributing to GLUT expression in in vivo 
models, especially when full heart homogenates are studied. Additionally, a study in dogs 
reported that the regional expression pattern of GLUT4 changes from predominant 
expression in right atrial appendages in the healthy heart, towards prominent expression in 
the left ventricle during the development of heart failure,98 indicating that the regulation of 
glucose uptake is not only cell, but also regionally dependent. In conclusion, increased 
GLUT1 expression in combination with increased GLUT4 translocation may be important 
contributing factors on the road towards cardiac hypertrophy and failure. 
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3.2 FA transporters 
The functioning of FA transporters in the pressure-overloaded heart is still underexplored. 
Although clear associations have been made among the development of cardiac 
hypertrophy, increased glucose utilization and suppressed FA oxidation in spontaneous 
hypertensive rats and in animals undergoing aortic constriction,85,99–101 less conclusive data 
are available on FA uptake. In vivo 14-[18F]-fluoro-6-thia-heptadecanoate positron emission 
tomography imaging showed increased FA uptake prior to a reduction in cardiac function in 
spontaneous hypertensive rat hearts,102 while ex vivo studies in Dahl salt-sensitive rats (a 
frequently used rodent model of cardiac hypertension) found a contradictory decrease in 
FA uptake concordantly with the progression of heart failure.76 After TAC surgery in mice, 
there is a modest reduction in mRNA expression of CD36 and FABPc, and a markedly 
decreased protein expression of CD36.65,66 A similar pattern for alterations in CD36 
expression was observed in another study where rats underwent suprarenal abdominal 
aorta banding, while no effect on FATP was found.103 Together, these data would indicate 
that FA uptake is reduced in the pressure-overloaded heart; however, it has to be noted 
that subcellular distribution of CD36 was not studied. 
To explore the role of CD36 in the pressure-overloaded heart more closely, both CD36 
overexpression and knockout models have been studied. It has been shown that cardiac-
specific overexpression of CD36 ameliorates cardiac dysfunction in mice undergoing TAC 
surgery.66 Additionally, a study in spontaneously hypertensive rats observed a reduction in 
CD36 levels that contributed to the development of cardiac hypertrophy.104 Moreover, an 
in vivo study on CD36-specific knockdown mice showed decreased fractional shortening and 
increased left ventricular end-diastolic diameter after TAC.105 This reduced cardiac function 
was also confirmed in vivo, where cardiac-specific ablation of CD36 accelerated the 
progression from compensated hypertrophy to severe heart failure in mice subjected to 
TAC. When this same group of mice was fed a diet containing medium-chain FAs, which can 
enter into the cardiomyocyte independently from CD36, these mice were protected from 
TAC-induced heart failure.106 
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Additional studies on cytoplasmic FA transporters, i.e. FABPc’s, showed that mice doubly 
deficient for FABP4 and FABP5 developed more severe heart failure after TAC compared to 
their wild-type littermates.107 However, another study revealed that FABP4 could be a 
possible positive regulator of cardiac hypertrophy, because mice specifically overexpressing 
cardiac FABP4 were more sensitive to develop cardiac hypertrophy after TAC when 
compared to wild-type animals.108 As a result, the exact role of cytoplasmic FABPs in the 
pressure-overloaded heart remains to be determined. 
3.3 Lactate and ketone body transporters 
Whereas FA and glucose transport in the pressure-overloaded heart have been studied in 
more detail, the relative importance of lactate and/or ketone bodies and their membrane 
transporters have remained unclear. Aubert et al.17 measured gene expression of MCT1 and 
of MCT2 in mice with TAC (as a model of compensated hypertrophy) and TAC plus small 
apical MI (as a model of heart failure) as compared to sham control animals. They found 
similar transporter expression levels in compensated hypertrophy or heart failure 
myocardium compared to control after 4-h fasting, but significantly increased MCT2 mRNA 
levels in both surgery groups as compared to controls after 24-h fasting (of note, fasting 
increases circulating ketone bodies). Their data suggest increased ketone body utilization in 
heart failure due to increased delivery of ketone bodies and gene regulatory 
reprogramming of ketone uptake and oxidation. Other studies focussed on the expression 
levels of these transporters in other types of cardiac failure. MCT1 protein levels were 
increased in models of chronic MI induced-congestive heart failure109 and volume overload 
induced-heart failure.46 A study in a rat model of acute myocardial ischaemia/reperfusion 
injury noted increased MCT4 mRNA and protein expression following global ischaemia and 
increased MCT1 mRNA and protein expression during the early stage of reperfusion.49 
Interestingly, a hypoxic environment is able to activate the MCT4 promotor (but not MCT1 
or MCT2) via HIF-1α.54 In general, expression of MCTs thus seems to be increased during 
heart failure, although the type of MCT might be depending on the type of heart failure. 
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While not focusing on the transporter level specifically, other studies took a closer look at 
the effect of PO on myocardial lactate and ketone body utilization. In contrast to what has 
been shown in hypoxia,110 studies with mice subjected to transverse91 and abdominal111 
aortic banding showed reduced lactate oxidation. This observation could either indicate 
that lactate oxidation is repressed in the pressure-overloaded heart, independent of 
substrate influx, or that less intracellular lactate is available to be oxidized due to decreased 
lactate uptake or plasma availability. 
In contrast to the observed reduction in lactate oxidation, ketone body oxidation seems to 
be increased in heart failure. Increased blood ketone body levels were found in non-diabetic 
congestive heart failure patients.112 In addition, a group of non-diabetic, lean, 
predominantly non-ischaemic advanced heart failure patients had increased serum βOHB 
and decreased myocardial βOHB levels, implicating increased myocardial ketone body 
utilization. This was accompanied by increased myocardial gene expression of several genes 
involved in ketone oxidation, D-β-hydroxybutyrate dehydrogenase (BDH) 1 and 2, and 3-
oxoacid CoA-transferase 1 (OXCT1, the gene encoding the rate limiting enzyme for 
myocardial oxidation of βOHB and AcAc, OXCT1).113 
Interestingly, cardiac-specific overexpression of BDH1 in a mouse model of PO ameliorated 
cardiac remodelling.114 Additionally, cardiac-specific knockout of OXCT1 resulted in adverse 
left ventricular remodelling under PO.115 These data suggest that enhanced ketone body 
utilization might be cardioprotective in the pressure-overloaded heart. Whether this 
enhanced ketone body oxidation is also linked to increased expression of ketone body 
transporters on the cellular surface of cardiomyocytes, or simply to differences in 
concentration gradient across the sarcolemma still needs to be determined. 
3.4 Amino acid transporters 
Little is known about the role of AA transporters in the pressure-overloaded heart. One of 
the scarce studies on this topic involved patients with congestive heart failure (CHF), and 
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reported a reduction in myocardial L-arginine uptake, which was associated with 38% lower 
ventricular CAT1 mRNA expression.116 Despite these limited data on AA transporters, 
several studies investigated other aspects of AA metabolism in relation to heart failure. 
Clear associations between altered AA metabolism and pathological remodelling are found. 
However, data on these associations are ‘divergent’ and seems to be depending on type of 
AAs and type and stage of heart failure. 
Elevated levels of plasma AAs are found in CHF patients116,117 and in animals subjected to 
TAC surgery.118 In contrast to these studies, Aquilani et al.119 observed decreased plasma AA 
levels in patients with CHF. These differences in AA levels among published studies could 
possibly be attributed to the fact that Aquilani et al. excluded patients with diabetes and/or 
insulin resistance, because it is known that these latter conditions are independently 
associated with increased plasma AA concentrations. In addition to increased plasma AA 
levels, increased intramyocardial (total free) AA concentrations are found in human failing 
right ventricles120 and in tissue of animals subjected to TAC121 or to a high-salt diet.76 These 
findings suggest that cardiac AA uptake is increased in the (pressure-overloaded) failing 
heart. Genes involved in AA degradation pathways were found down-regulated in TAC-
subjected mice, and impaired BCAA catabolism and intramyocardial accumulation of 
branched-chain alpha-keto acid (BCKA) were suggested to promote cardiac dysfunction in 
the pressure-overloaded heart.118,122 Reciprocally, pharmacological enhancement of BCAA 
catabolic pathways was able to preserve cardiac function in TAC-induced pressure-
overloaded hearts.123 Moreover, when Dahl salt-sensitive rats received drinking water 
supplemented with a mixture of BCAAs, their cardiac systolic function was preserved 
compared to rats receiving normal water.124 This suggests that increased availability of 
BCAAs, BCAA supplementation, and utilization of the pressure-overloaded heart could be 
cardioprotective, and that catabolic pathways could function as a potential therapeutic 
target. 
Most likely differences in altered AA homeostasis upon heart failure development relate to 
the type of AA, the type of heart failure, and the developmental stage. It has for instance 
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been shown that plasma levels of different AAs are reduced at different severity stages of 
heart failure.119 Moreover, intramyocardial BCAA levels and several other AA 
concentrations were significantly increased 1 week after TAC surgery, whereas this was no 
longer prominent after prolonged duration of TAC.121 A similar trend of increased BCAAs 
was found in the Dahl salt-sensitive rats, however, a distinct pattern in other AAs was 
described.76 Divergent AA levels have also been found in different studies of patients with 
heart failure. Patients with stage C heart failure had elevated plasma levels of 
phenylalanine, tyrosine, taurine, glutamate, ornithine, spermine, and spermidine as well as 
reduced citrulline, glutamine, and histidine levels,125 while in other studies on patients with 
severe heart failure reduced methionine, phenylalanine, tyrosine, histidine, threonine, 
homoserine, glutamine, and alanine levels were reported.77 Taken together, to provide 
accurate conclusions with respect to the role of specific AAs and their metabolism in the 
development of specific types of heart failure more research is required. Although the exact 
role of specific AA transporters in relation to these altered cardiac and plasma AA levels in 
distinct types of heart failure (including PO-induced) is yet to be defined, studies have at 
least indicated that AA metabolism plays a crucial role in the development of heart failure. 
4. Concluding remarks 
Altered cardiac energy metabolism is an important early contributor to the development of 
cardiac hypertrophy and failure and emerges as a suitable treatment target in PO. For 
glucose and FA, substrate availability and transport of substrates into cardiomyocytes are 
key-governing kinetic steps in their metabolic utilization. Therefore, regulating substrate-
specific transporter expression and/or their presence at the sarcolemma could be an 
interesting approach to manipulate substrate preference, restore altered energy 
metabolism, thereby prevent cardiac dysfunction or help rescue cardiac function in the 
pressure-overloaded heart. Available data suggest that GLUT1, GLUT4, and CD36 each play 
a pivotal role in the pressure-overloaded heart. Whereas the sarcolemmal presence of 
GLUT1 and of GLUT4 is increased, total GLUT4 and CD36 protein levels seem to be 
decreased in the pressure-overloaded heart (Figure 2, Table 2). However, it should be noted 
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that most of the underlying studies did not discriminate between PO-induced hypertrophy 
and PO-induced heart failure and that studies on CD36 expression did not make a distinction 
between subcellular and cell surface (sarcolemmal) content (Table 2). Moreover, it should 
be emphasized that, in addition to cardiomyocytes, metabolism is also altered in other cell 
types of the diseased heart (such as endothelial cells and fibroblasts). These distinct cell 
types actively crosstalk with cardiomyocytes and therefore should be considered as possible 
additional contributors to the development of failure in the pressure-overloaded heart.126 
Nonetheless, recovering an optimal substrate preference by specifically targeting processes 
involved in the regulation of the sarcolemmal localization of these specific transporters 
could be beneficial. The latter may comprise manipulation of subcellular transporter 
translocation or of their transcriptional regulation. For the heart exposed to PO, it can be 
deduced that CD36 expression and/or translocation should be stimulated to specifically 
increase FA uptake, and that GLUT4 expression and/translocation should be inhibited. For 
this, specific differences in the GLUT4 and CD36 translocation machineries, related to e.g. 
VAMPs and Rab effector proteins, may be exploited to manipulate cardiac substrate 
preference. Specifically, up-regulation of VAMP4 and down-regulation of Rip11 would 
stimulate CD36 translocation without affecting that of GLUT4.27 
It should be noted that rebalancing substrate uptake would only be advantageous when the 
pressure-overloaded heart is not simultaneously faced with periods of oxygen shortage, i.e. 
when it is solely relying on glycolysis as energy providing pathway, and that the 
effectiveness of such manipulation might depend on the stage of heart failure development. 
Additionally, with respect to the translation of the available findings on substrate 
transporters to humans, it should be kept in mind that most of the presented data originates 
from animal models. Whereas the clinical definition of heart failure was historically based 
on measurement of left ventricular ejection fraction, it currently restricts itself to stages at 
which clinical symptoms are present.2 This complexity makes animal modelling of heart 
failure more difficult, and translational aspects must, therefore, be interpreted with 
caution. Moreover, individuals with PO often present with comorbidities like obesity and 
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Type 2 diabetes. These comorbidities are known to affect cardiac metabolism in patients; 
for instance, obesity and Type 2 diabetes result in elevated FA oxidation rates.127,128 Further 
insight into what happens to FA transporters and other membrane transporters in these 
individuals may provide important information for early diagnostics and novel therapeutic 
treatment strategies to rescue the pressure-overloaded heart. 
Recent data also implicate a role for alternative substrates, such as lactate, ketone bodies, 
and AAs, in the pathophysiology of the pressure-overloaded heart. Increased availability 
and enhanced utilization of alternative substrates seem to be cardioprotective (Figure 2). 
Whether this enhanced utilization of ketone bodies and AAs is triggered by increased 
expression of their specific transporters at the cellular membrane, or simply related to 
differences in concentration gradients of these substrates needs to be determined. Future 
research focusing on the role of transporters of the alternative substrates in PO might lead 
to new therapeutic strategies to combat PO-induced cardiac hypertrophy and failure. 
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Table 1. Cardiac membrane substrate transporters and their expression in pressure-overloaded hearts.  
 
 
 
 
 
 
 
 
 
 
 
 
For glucose, fatty acid, ketone body, and lactate transporters, the most predominant cardiac transporters are indicated. For the majority of other (less important) substrate transporters only total cardiac mRNA 
levels have been investigated. Moreover, the expression levels were often relatively low when compared with the expression levels of the predominant transporters, were investigated in foetal heart, or were 
determined in other areas of the heart than left ventricle. −, no response; −/+, translocation disputed; +, moderate response; ++, strong response; +++, very strong response; ↑, up-regulation of sarcolemmal 
substrate specific transporters under the condition of pressure overload; ↓, down-regulation of sarcolemmal substrate specific transporters under the condition of pressure overload; n.k., translocation not 
known. *,  translocation of the specific transporters was not investigated. 
 
Transporters 
 
Genes 
 
Predominant substrates 
Physiological triggers for 
translocation 
 
Pressure overload 
 
References 
Contraction Insulin 
 
Glucose transporters 
GLUT 1 (predominant) 
GLUT 3 
GLUT 4 (predominant) 
GLUT 8 
GLUT 10 
GLUT 11 
GLUT 12 
SGLTs 
 
Fatty acid transporters 
FAT/CD36 (predominant) 
FATP1 
FATP6 
FABPpm 
 
Lactate and ketone body 
transporters 
MCT1 (predominant) 
MCT2 
MCT3 
MCT4 (predominant) 
 
Amino acid transporters 
LAT2 
y+LAT2 
Acs-1 
CATs 
 
 
SLC2A1 
SLC2A3 
SLC2A4 
SLC2A8 
SLC2A10 
SLC2A11 
SLC2A12 
SLC5As 
 
 
CD36 
SLC27A1 
SLC27A6 
GOT2 
 
 
 
SLC16A1 
SLC16A7 
SLC16A8 
SLC16A3 
 
 
SLC7A8 
SLC7A6 
SLC7A10 
SLC7As 
 
 
Glucose, galactose, mannose, glucosamine 
Glucose, galactose, mannose, xylose 
Glucose, glucosamine 
Glucose, fructose, galactose 
Glucose, galactose 
Glucose, fructose 
Glucose 
Glucose, galactose, mannose, fructose, urea, water 
 
 
LCFAs and VLCFAs 
LCFAs and VLCFAs 
LCFAs and VLCFAs 
LCFAs 
 
 
 
Lactate, pyruvate, ketone bodies 
Pyruvate, Lactate, ketone bodies 
Lactate 
Lactate, ketone bodies 
 
 
Neutral L-amino acid 
Cationic amino acids; Na+/ large neutral amino acids 
Small neutral amino acids 
Cationic-amino-acid (and Na+-dependent 
neutral-amino-acid) 
  
 
+ 
n.k. 
++ 
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
 
 
++ 
- 
n.k. 
+ 
 
 
 
n.k. 
n.k. 
n.k. 
n.k. 
 
 
n.k. 
n.k. 
n.k. 
n.k. 
 
 
+ 
n.k. 
+++ 
+ 
n.k. 
n.k. 
- 
n.k. 
 
 
++ 
- 
n.k. 
-/+ 
 
 
 
n.k. 
n.k. 
n.k. 
n.k. 
 
 
n.k. 
n.k. 
n.k. 
n.k. 
 
 
 
↑ 
 n.k. 
↑  
n.k. 
n.k. 
n.k. 
n.k. 
n.k. 
 
 
↓*  
n.k. 
n.k. 
↓*  
 
 
 
n.k. 
n.k. 
n.k. 
n.k. 
 
 
n.k. 
n.k. 
n.k. 
n.k. 
 
 
 
               
          
           (Schwenk et al. 2010)27 
               (Waller et al. 2013)63  
            (Maria et al. 2015)64  
           (Szablewski et al. 2017)21 
 
 
 
 
        (Schwenk et al. 2010)27  
        (Dong et al. 2015)65 
      (Guo et al. 2018)66  
 
 
 
           
         (Halestrap et al. 2012)47  
         (Adeva-Andany et al. 2014)42 
 
 
 
     
    (Fotiadis et al. 2013)57 
    (Hyde et al. 2003)56 
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Table 2. Overview of available animal studies reporting on transporter levels in PO-induced hypertrophy and heart failure. 
 
AAB, abdominal aortic banding; ACC, ascending aortic constriction; AngII, angiotensin II; CH, compensated hypertrophy; CHF, congestive heart failure; CM, cardiomyocytes; HF, heart failure; n.a., not applicable; n.d., not determined; 
PE, phenylephrine; PM, plasma membrane; SHR, spontaneous hypertensive rats; TAC, transverse aortic constriction.
Pressure overload- 
induced heart failure 
models 
Cardiac 
hypertrophy 
Time 
Course 
PO 
Needle size 
(TAC) 
Cardiac 
functional 
changes 
Transporter expression changes Gene or protein 
expression 
analysis 
Ref. 
Reduced cardiac 
function models 
 
    
EF (%) 
 
FS (%) 
 
GLUT1 
 
GLUT4 
 
CD36 
 
FATP 
 
FABP 
 
MCT2 
  
SHR model 
TAC model (Rats) 
SHR model 
TAC model (Mice) 
(Comp. hypertrophy) 
(Heart Failure) 
TAC model (Mice) 
AAB model (Rats) 
TAC model (Mice) 
TAC model (Mice) 
Dahl Salt model (Rats 17W) 
TAC model (Mice) 
TAC model (Rats) 
SHR model 
TAC model (Mice) 
n.d. 
Yes 
n.d. 
 
CH 
HF 
Yes 
Yes 
Yes 
Yes 
CHF 
Yes 
Yes 
n.d. 
Yes 
n.a. 
17-19 wks 
n.a. 
 
1 month 
1 month 
4 wks 
9 wks 
8 wks 
8 wks 
n.a. 
2 months 
17-19 wks 
n.a. 
6 wks 
n.a. 
0.6 mm clip 
n.a. 
 
26-28 G 
26-28 G + MI 
30 G clip 
20 G 
27 G 
27G 
n.a. 
27 G 
0.6 mm clip 
n.a. 
27 G 
n.d. 
n.d. 
n.d. 
 
n.d. 
n.d. 
9% ↓ 
9% ↓ 
21% ↓ 
21% ↓ 
n.d. 
40% ↓ 
n.d. 
n.d. 
15% ↓ 
n.d. 
n.d. 
n.d. 
 
n.d. 
n.d. 
7% ↓ 
9% ↓ 
14% ↓ 
14% ↓ 
19% ↓ 
n.d. 
n.d. 
n.d. 
n.d. 
↑ 
↑ 
n.d. 
 
n.d. 
n.d. 
↑ 
n.d. 
= 
↑ 
↑ 
n.d. 
↑ 
n.d. 
n.d. 
↓ 
↓ 
n.d. 
 
n.d. 
n.d. 
↑ 
n.d. 
= 
↓ 
↓ 
n.d. 
↑ 
n.d. 
↓ 
n.d. 
n.d. 
↓ 
 
n.d. 
n.d. 
n.d. 
↓ 
↓ 
↓ 
↓ 
↓ 
n.d. 
= 
n.d. 
n.d. 
n.d. 
n.d. 
 
n.d. 
n.d. 
n.d. 
= 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
 
↑ 
↑ 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
mRNA 
Protein (Total) 
Protein (Total) 
 
mRNA 
mRNA 
Protein (Total) 
Protein (Total) 
Protein (Total) 
mRNA 
mRNA 
Protein (Total) 
Protein (PM) 
Protein (PM) 
Protein (PM) 
(Paternostro et al.)81 
(Tian et al.)85 
(Lauzier et al.)104 
 
(Aubert et al.)17 
(Aubert et al.)17 
(Pereira et al.)92 
(Dobrzyn et al.)103 
(Dong et al.)65 
(Dong et al.)65 
(Kato et al.)76 
(Guo et al.)66 
(Tian et al.)85 
(Lauzier et al.)104 
(Zhabyeyev et al.)91 
Unaltered cardiac function 
models 
 
SHR model 
ACC model (Mice) 
TAC model (Mice) 
TAC model (Mice) 
Dahl Salt model (Rats, 11W) 
 
 
Yes 
Yes 
Yes 
Yes 
Yes 
 
 
n.a. 
4 wks 
6 wks 
5 wks 
n.a. 
 
 
n.a. 
30 G clip 
27 G 
27 G 
n.a. 
 
 
4% ↑ 
= 
n.d. 
= 
n.d. 
 
 
6% ↑ 
= 
= 
n.d. 
= 
 
 
↑ 
↑ 
n.d. 
n.d. 
= 
 
 
↓ 
= 
n.d. 
n.d. 
↑ 
 
 
n.d. 
n.d. 
↓ 
↓ 
= 
 
 
n.d. 
n.d. 
↑ 
n.d. 
n.d. 
 
 
n.d. 
n.d. 
= 
n.d. 
n.d. 
 
 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
 
 
Protein (Total) 
Protein (Total) 
Protein (Total) 
Protein (Total) 
mRNA 
 
 
(Wang et al.)82 
(Pereira et al.)94 
(Steinbusch et al.)105 
(Sung et al.)106 
(Kato et al.)76 
In vitro models 
 
Neonatal-rat-CMs + AngII 
Neonatal-rat-CMs + PE 
Adult-rat-CMs + PE 
 
 
Yes 
n.d. 
Yes 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
↑ 
↑ 
n.d. 
 
 
↑ 
↑ 
↓ 
 
 
n.d. 
n.d. 
n.d. 
 
 
n.d. 
n.d. 
n.d. 
 
 
n.d. 
n.d. 
n.d. 
 
 
n.d. 
n.d. 
n.d. 
 
 
Protein (PM) 
Protein (PM) 
mRNA 
(GLUT1/GLUT4 
ratio) 
 
 
(Stuck et al.)86 
(Fischer et al.)87 
(Montessuit et al.)80 
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Abstract 
Patients with type 2 diabetes (T2D) and/or insulin resistance (IR) have an increased risk for 
the development of heart failure (HF). Evidence indicates that this increased risk is linked to 
an altered cardiac substrate preference of the insulin resistant heart, which shifts from a 
balanced utilization of glucose and long-chain fatty acids (FAs) towards an almost complete 
reliance on FAs as main fuel source. This shift leads to a loss of endosomal proton pump 
activity and increased cardiac fat accumulation, which eventually triggers cardiac 
dysfunction. In this review, we describe the advantages and disadvantages of currently used 
in vitro models to study the underlying mechanism of IR-induced HF and provide insight into 
a human in vitro model: human embryonic stem cell-derived cardiomyocytes (hESC-CMs). 
Using functional metabolic assays we demonstrate that, similar to rodent studies, hESC-CMs 
subjected to 16h of high palmitate (HP) treatment develop the main features of IR, i.e., 
decreased insulin-stimulated glucose and FA uptake, as well as loss of endosomal 
acidification and insulin signaling. Taken together, these data propose that HP-treated 
hESC-CMs are a promising in vitro model of lipid overload-induced IR for further research 
into the underlying mechanism of cardiac IR and for identifying new pharmacological agents 
and therapeutic strategies. 
 
 
 
 
 
 
 
 
|  Human embryonic stem cell-derived cardiomyocytes to study insulin resistance 
 
105 
 
1. Introduction 
Type 2 diabetes (T2D) is a growing health problem worldwide. Fueled by life style changes, 
such as increased intake of energy-rich food and sedentary lifestyle, the diabetes epidemic 
has grown parallel with the obesity epidemic1. The global prevalence of diabetes among 
adults has increased dramatically in recent decades, with 4.7% of adults reported with T2D 
in 1980 and 8.5% in 20142. This major increase in T2D is associated with an increased risk 
for the development of heart failure (HF) and other cardiovascular diseases, emphasizing 
the serious need for research in this particular field3-6. Insulin resistance (IR), a hallmark of 
T2D7,8, is a complex metabolic disorder that occurs upon persistent exposure of the 
respective organ or tissue to fat. The IR heart has lost the ability to respond adequately to 
normal plasma levels of insulin, i.e., the rate of insulin-stimulated (GLUT4-mediated) 
glucose uptake is reduced9,10. The consequent alterations in substrate metabolism 
eventually lead to impaired cardiac function. Despite improvements in primary and 
secondary prevention over the past years, patients with T2D or IR still have a 2–4 times 
higher risk of developing HF11,12. This highlights the importance of further elucidating the 
pathophysiological mechanism behind IR-induced HF. Development of representative 
model systems to investigate the molecular mechanism will facilitate the search for new 
targets to replace or support the current treatment strategies. 
In recent decades, several animal models have been developed to investigate the 
underlying mechanism of IR-induced HF. For further in depth unraveling of this molecular 
mechanism, cellular models of the hearts of these animals would be preferred, since they 
have the additional advantage of allowing precise control of the experimental environment, 
including pharmacological manipulation13,14. However, the use of cellular models obtained 
from experimental animals also comes with limitations, as they do not perfectly correlate 
to normal human cardiac physiology. To closer reflect the human situation, human in vitro 
models would be particularly beneficial in exploring the underlying mechanisms of cardiac 
disease. However, primary human cardiac cells or human heart tissue cannot be obtained 
easily. Therefore, the emerging human stem cell-derived cardiomyocytes could be a useful 
tool for drug discovery and the development of personalized treatment strategies. 
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In this review, we provide an overview of the current knowledge and use of human stem 
cells to study IR and the potential application of human stem cell-derived cardiomyocytes 
(hSC-CMs) for studying cardiac IR. First, we summarize the available human cardiomyocyte 
sources after which we provide more details about the basic characteristics of stem cell-
derived cardiomyocytes (including human induced pluripotent and embryonic stem cell-
derived cardiomyocytes (hiPSC-CMs and hESC-CMs, respectively)) and the use of cell models 
to study IR. Finally, we present novel metabolic data on hESC-CMs as a promising human in 
vitro model for the study of cardiac IR. 
2.  Sources of human cardiomyocytes 
2.1. Primary cardiac tissue 
Cardiac tissue biopsies, obtained during cardiac surgery, can be used for the isolation of 
cardiomyocytes. These primary sources directly represent the situation in the human heart. 
However, when isolating cardiomyocytes, tissues need to be immersed into a collagenase-
containing bath as quickly as possible, since snap-frozen or fixated tissue is unsuitable for 
cardiomyocyte isolation15. A major drawback of this collagenase treatment to digest the 
heart tissue is the low yield. Moreover, cardiomyocytes are terminally differentiated cells, 
making it difficult to obtain sufficient cells for metabolic measurements. Additionally, 
biopsies are usually taken at a localized area of the heart, during surgery or with catheters, 
and might not be representative for the characteristics and function of the left ventricle 
(LV). Removing cardiac tissue from healthy individuals is not ethically approved and there is 
a limited availability of unused donor hearts, which prevents us from comparing healthy 
individuals to patients with specific cardiac disease. Moreover, cardiac biopsies are mainly 
obtained from patients with end-stage HF and are therefore not representative of the early 
pathological changes in the heart16. 
2.2. Commercially available cell lines 
Alternatives to these cardiac biopsies are the commercially available proliferating human 
cell lines, such as AC16 and SV40 cells. The AC16 cell line was gained by fusing primary 
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cultures of adult ventricular heart tissue with SV40 transformed human fibroblasts17. This 
cell line is stable, expresses cardiomyocyte specific markers (α-MHC, β-MHC, α-Actin, 
troponin I), and displays electrophysiological properties, but detailed information on its 
metabolic characteristics is not available. A number of other immortalized human SV40 
cardiomyocyte lines are also commercially recommended. However, literature on their 
cardiomyocyte specific characteristics is lacking. Before these cell lines can be deemed 
suitable for the study of cardiac metabolism, more research into their cardiac and metabolic 
properties has to be conducted18,19. 
2.3. Human stem cell-derived cardiomyocytes 
In the last decade, great efforts have been made to identify less-invasive and more 
representative sources of human cardiomyocytes for various applications, especially for 
drug cardiotoxicity screening, myocardial regeneration, and drug discovery20-23. The human 
pluripotent stem cell appears to be a suitable candidate, because of its potential to 
proliferate and differentiate into various cell types including cardiomyocytes24-26. Human 
stem cell-derived cardiomyocytes, such as hiPSC-CMs and hESC-CMs have attracted 
considerable attention. Specifically, based on their myogenic gene profile and contractile 
properties they appear to be functional cardiomyocytes27-29. hiPSCs are generated by 
overexpressing embryonic transcription factors in somatic cells, such as fibroblasts30. The 
major advantage of hiPSCs is that they can be obtained via minimally invasive procedures; 
they can usually be isolated from skin biopsies. Besides the skin biopsies, new methods have 
become available to obtain hiPSCs, namely from urine and blood31-33. These methods 
appear to be non-invasive, relatively simple, cost-effective, and a reasonably quick process 
compared to isolation from skin biopsies and hold great promise33,34. During fibroblast 
reprogramming and differentiation of fibroblast-derived hiPSCs, the patient-specific genetic 
profile is retained. In this way, cardiomyocytes from patients with specific metabolic or 
cardiac disease related mutations can be produced, thus opening a window for 
personalized, patient-specific drug discovery33,35. However, patient specific epigenetic 
markers are also maintained during cellular reprograming to hiPSCs, which might influence 
the differentiation process. Conversely, hESCs are derived from human healthy blastocysts 
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that are surplus to the requirements of in vitro fertilization, without the influence of genetic 
mutations and epigenetic differences. They are commercially available, thus a standardized 
cell line can be obtained on a regular basis. Although hESCs are less suitable for a 
personalized-medicine approach, as they are obtained from a healthy donor, they have 
proven useful as in vitro model for testing the safety and efficacy of human drugs and for 
studying underlying mechanisms in the development of cardiac disease, independent of 
patient-specific genetic abnormalities. 
3. Basic characteristics of human stem cell-derived cardiomyocytes 
3.1. Structural, molecular and electrophysiological characteristics 
hSC-CMs differ from adult human cardiomyocytes with respect to shape, sarcomeric 
organization and receptor expression. Adult human cardiomyocytes have a large and 
cylindric shape, aligned sarcomeres and large numbers of mitochondria, whereas hSC-CMs 
have a smaller and oblong morphology, sarcomeres are short and disorganized and less 
mitochondria are present. It has however been pointed out that maturity can be achieved 
by prolonged culture of these hSC-CMs (up to 100 days), thereby enhancing structural 
organization and functional performance over time36-38. Additionally, the transcriptional or 
molecular profile of hSC-CMs differs from undifferentiated stem cells. Important differences 
include the loss of pluripotency markers (OCT4, NANOG, klf4, POU5F1, SOX2) and the 
upregulation of mesodermal and cardiac myofilament markers29,36,39-41. During the 
differentiation process, an expression pattern can be distinguished of early and late 
cardiomyocyte markers. After 5–6 days of differentiation the early markers (GATA-4, ISL1 
and KDR) become highly expressed. The expression level of late markers (NKX2–5, TBX5, 
MEF2C, HAND1/2) peaks around day 8–9, followed by an upregulation of myofilament 
genes (TNNT2 and MYH6) at day 8–1042,43. Twenty to 30 days differentiated cardiomyocytes 
showed homogeneity among cells based on expression levels of the above-mentioned 
markers. Furthermore, hSC-CMs are generally characterized as spontaneously, synchronic 
beating cells derived from human stem cells. The capability of a cell to contract depends on 
its capability to generate action potentials44,45. Whether action potential (AP) phenotype, 
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ion channels and calcium handling in hSC-CMs are similar to the adult heart has been 
investigated extensively. Similar to human adult cardiomyocytes, a heterogeneous 
population of atrial-, nodal-, or ventricular-like cells can be distinguished in hSC-CMs based 
on AP phenotypes26,46. However, these AP characteristics seem to vary between culture 
conditions and culture time, possibly undermining the correctness of this 
classification38,47,48. To what extent hSC-CMs represent the human adult heart in terms of 
structural, molecular and physiological characteristics remains debatable. 
3.2. Metabolic properties 
In terms of metabolism, adult cardiomyocytes are highly active, and for the synthesis of 
ATP, these cells are mainly (50–70%) dependent on oxidative FA metabolism. In 
comparison, embryonic and fetal cardiomyocytes mainly rely on glycolysis. For the uptake 
of glucose the class 1 facilitative transporters (GLUT1, GLUT2, GLUT3 and GLUT4) are the 
most abundant. Throughout the embryonic period, GLUT1 is expressed ubiquitously and is 
considered responsible for basal glucose uptake. In all forms of hESCs as well as in 
fibroblasts glucose uptake is mainly facilitated by the constitutively expressed GLUT1 
transporter49. The human adult heart, conversely, abundantly expresses GLUT4, a high-
affinity insulin sensitive glucose transporter, next to GLUT150. FA uptake in the adult heart 
is mainly facilitated by fatty acid translocase (CD36)51. Whether these transporters are 
present in hSC-CMs and to what extent they contribute to substrate uptake in hSC-CMs has 
not been studied so far, but will be further discussed in Section 6. These changes in 
transporter content (at least as studied so far for the GLUTs) are expected to occur in 
concordance with changes in metabolism. Whereas stem cells are mainly dependent on 
glycolysis, a switch towards mitochondrial oxidative metabolism occurs upon differentiation 
into cardiomyocytes. Compared to hSCs, hSC-CMs have been shown to have increased 
mitochondrial oxygen consumption and reduced glycolytic reliance28,52,53. Moreover, this 
switch is accompanied by a substantial increase in mitochondrial biogenesis, higher 
expression of genes and proteins related to oxidative phosphorylation, FA oxidation and 
lipolysis, which changes continue during the maturation of cardiomyocytes in culture. 
Furthermore, these unique metabolic properties of cardiomyocytes can be used as a 
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selection method to generate purified cardiomyocytes. For instance, treatment of 20 day-
differentiated hiPSC-CMs with lactate, which can only be metabolized via oxidative 
phosphorylation, was shown to result in 99% purification of hSC cultures53. These data 
suggest that hSC-CMs have the potential to use oxidative metabolic pathways, like adult 
cardiomyocytes54-57, and therefore could potentially be useful to study the underlying 
molecular mechanisms of human metabolic diseases. 
4. In vitro and ex vivo rodent models of lipid-induced insulin resistance 
In recent decades, several animal models have been developed to investigate the 
underlying mechanism of HF in T2D. Many of these models are based on lipid overload. For 
instance, the chronic exposure of rodents to a HP diet is often used to achieve lipid 
overload-induced IR in skeletal muscle58,59 and heart60-63. These animal models allow the 
metabolic changes to be studied in relation to cardiac structural and functional changes. 
Additionally, ex vivo primary cell culture models, such as neonatal rat cardiomyocytes, 
isolated adult rat and mouse cardiomyocytes, as well as in vitro immortal mouse atrial 
cardiomyocyte cell lines, such as HL-1 cells, are commonly used to study cardiac 
metabolism14. Together, these in vitro, ex vivo and in vivo animal models were instrumental 
in unraveling the mechanism of the onset of lipid-induced IR. This mechanism includes (i) a 
rapid CD36 translocation to the sarcolemma and chronically increased FA uptake, (ii) 
subsequent accumulation of toxic lipid intermediates (e.g., ceramides), (iii) inhibition of 
insulin signaling (as determined by decreased phosphorylation of protein kinases in the 
canonical insulin signaling cascade, such as Akt, upon insulin treatment), (iv) decreased 
insulin-stimulated glucose and FA uptake, ultimately leading to cardiac dysfunction. 
The use of these cellular models allows full control of the experimental environment 
including pharmacological manipulation13,14. Though, isolated cells lack the inter-cellular 
and intra-organ contacts, are not subjected to a preload or afterload and 
hormonal/neuronal changes, and therefore do not perfectly represent the situation on the 
whole organ. Furthermore, cardiac cells from animal models are genetically not equivalent 
to their human counterparts, and subcellular/organellar differences in these cells occur 
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between species16,64. Primary human cardiac cells and human heart tissue can, however, 
not be obtained easily. Therefore, the emerging hSC-CMs could be a useful new tool for 
drug discovery and the development of personalized treatment strategies. 
5. Insulin resistance in human induced pluripotent stem cells 
As described earlier, considerable research has been conducted on hSCs and their derived 
cardiomyocytes. However, detailed information on their functional metabolic properties 
and whether IR can modulate metabolism in these cells is scarce. As recently shown65,66, 
iPSCs and iPSC-derived skeletal myotubes possess the intrinsic ability to acquire IR, including 
the expected metabolic changes. In iPSCs from patients with a genetic insulin receptor 
defect, IR can lead to reduced mitochondrial oxidative capacity, decreased expression of 
glucose metabolism related genes, and increased reliance on anaerobic metabolism. 
Interestingly, after differentiation, the skeletal myotubes, derived from these patient iPSCs 
still showed impaired insulin signaling and insulin-stimulated glucose uptake, decreased 
mitochondrial function, impaired glycogen synthase activity, and glycogen accumulation 
when compared to myotubes of control subjects. These data indicate that the insulin 
resistant phenotype is conserved after reprogramming and re-differentiation into human 
skeletal myotubes. Moreover, a decrease in gene expression of insulin-regulated genes 
(RAD1, HK2 and GLUT4) was found65-67. Whether these findings on hiPSC-derived skeletal 
myotubes also apply to hiPSC-CMs or hESC-CMs remains unknown. 
Another study68 aimed at developing an in vitro model of diabetic cardiomyopathy, using 
hiPSC-CMs from healthy donors. hiPSC-CMs were cultured without glucose to force the cells 
towards FA utilization. The investigators hypothesized that additional exposure to a diabetic 
environment would promote features similar to diabetic cardiomyopathy. A diabetic 
environment was mimicked through culture in a maturation medium including 10 mM 
glucose and relevant concentrations of endothelin-1 and cortisol. Compared to cells on 
standard maturation medium, cells exposed to this diabetic environment showed 
disorganized sarcomere structures, altered calcium transients, cellular hypertrophy, 
intracellular lipid accumulation and oxidative stress. Further, an upregulation was shown of 
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genes involved in the Krebs cycle, mitochondrial electron transport chain, and glucose 
metabolism, whereas a downregulation was observed of genes controlling protein synthesis 
and the cellular response to dysfunctional protein production. These data indicate that 
hiPSC-CMs exposed to a diabetic milieu recapitulate a diabetic cardiomyopathic phenotype 
in vitro68. 
The above findings65,66,68, each in different hiPSC models of IR and with distinct outcomes, 
may relate to differences in genetic background between the individual patients and 
maintained residual epigenetic differences during cellular reprogramming. Consequently, 
the establishment of an in vitro model without genetic variation would allow us to study the 
underlying mechanism of IR independent of genetic mutations. 
6. Insulin resistance in human embryonic stem cell-derived cardiomyocytes 
To our knowledge, it has not been investigated whether hESC-CMs can function as a suitable 
in vitro model to study cardiac IR. In previous in vitro studies on rodent cell lines, prolonged 
HP treatment triggered IR with defects in insulin signaling, substrate metabolism, and also 
diminished contractile function60,61,63. In the current experimental study, we differentiated 
hESCs into functional cardiomyocytes to study the impact of HP-induced IR on insulin 
signaling and cardiac metabolism in hESC-CMs. We aimed at establishing a human in vitro 
model to study the underlying mechanism of cardiac IR. Promising data on this new human 
in vitro model are described in more detail in the next paragraphs. 
6.1. Differentiation of hESCs towards hESC-CMs 
hESCs were differentiated into cardiomyocytes for 30 days. It has been described that hSC-
CMs at this point already express various features specific for human cardiomyocytes even 
though they might not be fully matured yet42,43,69. After 30 days of differentiation, > 30% of 
the cells showed spontaneous contraction and a robust induction (50 to 600-fold) of the 
expression of key cardiac sarcomeric markers (Fig. 1A), thus confirming differentiation of 
hESCs towards functional cardiomyocytes. Although these results are in agreement with 
reports from other groups29,36,42,43, it should be noted that the observed levels are not 
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closely comparable to the levels measured in human fetal or LV heart tissue. Nevertheless, 
these data indicate that we were able to differentiate hESCs into hESC-CMs, keeping in mind 
that the contractile properties still depict an incompletely matured phenotype. 
 
Figure 1. Differentiation of human embryonic stem cells into cardiomyocytes. Human embryonic stem cells (hESCs) were kindly 
provided by the Wicell Research Institute (Madison, WI) and subsequently maintained and differentiated for 30 days into hESC-CMs 
according to manufacturer's protocol (Gibco) as described previously81. Quantitative RT-PCR analysis of cardiomyocyte specific 
genes (A) and substrate transporter genes (B) was performed upon differentiation towards hESC-CMs. TATA box binding protein 
was used as housekeeping gene and data were normalized against undifferentiated cells, whereas human fetal whole heart (pooled 
from 4 hearts) and adult left ventricle (LV) tissue (pooled from 3 hearts) were used as positive controls. Immunoblot images of 
GLUT4 (C) and CD36 (D) are shown for hESCs (u) and hESC-CMs (d). Human, mouse and rat heart tissues and adult rat 
cardiomyocytes (aRCM) were used as positive controls whereas mouse and rat liver tissues served as negative controls. Cellular 
acidification rates (ECAR) (E), as a measure for glycolytic rate, and oxygen consumption rates (OCR) (F) were determined with a 
Seahorse device (Agilent; Seahorse, North Billerica, MA, US), according to the manufacturer's XF Glycolysis Stress protocol, using 
glucose (10 mM), oligomycin (1 μM), and 2-deoxy-d-glucose (50 mM). Values are displayed as mean ± S.E.M. (n = 3). Data were 
analyzed by using two-sided Student t-test and considered statistically significant at p < 0.05. *p < 0.05 compared to hESCs. 
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To obtain information about the specific metabolic properties of the 30 days differentiated 
hESC-CMs, we examined gene and protein expression levels of the specific glucose- and 
fatty acid transporters (GLUT4 and CD36, respectively), glycolytic capacity, and oxygen 
consumption rate in biological replicate samples. GLUT4 and CD36 mRNA levels were 5.1-
fold and 10.1-fold increased, respectively, in hESC-CMs as compared to hESCs, suggesting 
that the differentiating cells are switching towards a more mature phenotype (Fig. 1B). 
These findings on mRNA level were confirmed by western blot analysis where hESC-CMs 
showed increased expression of both GLUT4 (Fig. 1C) and CD36 (Fig. 1D) compared to hESCs, 
although it should be noted that GLUT4 and CD36 levels are several orders of magnitude 
lower than human fetal and adult cardiac tissue levels. Mitochondrial respiration 
measurements (Seahorse analyser) showed a 73% lower glycolytic rate (ECAR activity) in 
the hESC-CMs as compared to hESCs (Fig. 1E) and an increased oxygen consumption rate 
(Fig. 1F). In this respect, our 30 days differentiated hESC-CMs more closely resemble the 
(oxidation-dependent) human adult heart compared to the (glycolysis-dependent) fetal 
heart. Taken together, the presence of substrate transporters in hESC-CMs and the switch 
to aerobic metabolism offers potential for studying insulin signaling and other metabolic 
pathways in these cells. 
6.2. Lipid overload induces IR in hESC-CMs 
To examine the onset of lipid overload-induced IR in hESC-CMs, these cells were cultured in 
media with HP and then assessed on parameters of insulin sensitivity in biological replicate 
samples. Using a similar protocol as we have previously established to induce IR in HL-1 
cells63, we exposed 30 days differentiated hESC-CMs to 250 μM HP and 50 nM insulin for 
16 h (further referred to as HP treatment). Additionally, a short-term 100 nM insulin 
stimulus was given to evaluate whether the IR state has fully developed within these cells 
by assessing established metabolic and subcellular parameters of IR. Similar to rodent 
cardiomyocytes, hESC-CMs showed increased Akt and AS160 phosphorylation (2.0-fold and 
1.7-fold, respectively) upon insulin stimulation (Fig. 2A–B). Additionally, uptake of [3H]-
deoxyglucose and of [14C]-palmitate was significantly increased upon insulin stimulation. 
These observations indicate that 30 days differentiated hESC-CMs are insulin sensitive 
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under basal conditions. When cells were pre-treated with HP, both the activity of insulin 
signaling related proteins as well as cellular substrate uptake did not change upon insulin 
stimulation (Fig. 2C–D), suggesting that lipid overload induces IR in hESC-CMs. Furthermore, 
glycogen content was 58% lower in HP-treated hESC-CMs as compared to untreated cells 
(4.1 ± 0.4 and 1.7 ± 0.2 μg/106 cells in hESCs versus hESC-CMs, respectively; p < 0.01), 
suggesting that glycogen synthesis is also decreased. This is in line with other studies 
showing decreased glycogen synthesis in T2D patients and first degree-relatives70,71. 
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Figure 2. Lipid overload leads to insulin resistance (IR) and impairment of vacuolar-type H+-ATPase (vATPase) function in human 
embryonic stem cell-derived cardiomyocytes (hESC-CMs). hESC-CMs were cultured under control or high palmitate conditions 
(250 μM palmitate; 50 nM insulin) for 16 h to induce IR, followed by short-term (30 min) insulin stimulation (100 nM) on day 31 for 
measurements of insulin sensitivity. A–B) Protein expression levels of insulin signaling related proteins, phospho-Akt-Ser473 (p-Akt) 
and phospho-AS160-Thr642 (p-AS160). Insulin receptor beta (IRβ) was used as loading control. C–D) Glucose- and fatty acid uptake 
in hESC-CMs, determined by means of [3H]-deoxyglucose and [14C]-palmitate, respectively (n = 4). E) v-ATPase function is measured 
by means of cellular chloroquine accumulation60. hESC-CMs were treated with [3H]-chloroquine with/without 100 nM Bafilomycin 
A (Baf A, a potent v-ATPase inhibitor) for 25 min. The Baf A sensitive component of the total cellular chloroquine accumulation 
reflects v-ATPase activity (n = 3). F) Schematic presentation of lipid-induced v-ATPase inhibition and its consequences for insulin 
sensitivity and contractile function (adapted with permission from 60). When long-chain fatty acid (FA) supply is low, the FA 
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transporter CD36 is primarily found in endosomes. The v-ATPase V0 sub-complex, which is integral to the endosomal membrane, is 
assembled with the cytosolic V1 sub-complex allowing for acidification of the endosomal lumen. Upon chronic lipid oversupply, when 
FA uptake surpasses the cellular metabolic needs, a series of events is triggered: [1] Increased CD36-mediated FA uptake results in 
elevated intramyocellular FA levels [2]. FAs cause the V1 and V0 sub-complexes to dissociate. Therefore, V1 is shifted into the soluble 
cytoplasm [3]. The disassembly of v-ATPase leads to endosomal alkalinization [4]. Increased endosomal pH triggers the 
translocation of CD36 vesicles to the cell surface [5]. Palmitate overload eventually culminates into loss of insulin sensitivity and 
contractile function. Data are expressed as mean ± S.E.M. Data were analyzed by the Mann-Whitney U test and considered 
statistically significant at *p < 0.05. Data were normalized to control (A–D) or Baf A (E). 
Our group has recently unveiled a novel mechanism underlying lipid overload-induced IR. 
This includes inhibition of vacuolar H+-ATPase (v-ATPase), a resident protein in membranes 
of acidic organelles, such as endosomes, which are the storage compartments for CD3660. 
V-ATPase is responsible for maintaining endosomal acidification by means of its proton 
pumping activity. We have shown that lipid overload directly impairs v-ATPase function, 
causing loss of endosomal acidification. Since proper endosomal acidification is necessary 
for intracellular CD36 retention72, the alkalinized endosomes cannot harbor CD36 anymore, 
so that it translocates to the cell surface to increase fatty acid uptake, the key step in lipid 
overload-induced IR. The degree of endosomal acidification can be assessed by cell-
associated radioactivity upon incubation of cells with tracer amounts of the divalent weak 
base [3H]chloroquine, as previously established72. Fig. 2E shows that hESC-CMs exposed to 
HP display a reduction of cell-associated [3H]chloroquine accumulation compared to 
untreated control cells, indicating impairment of v-ATPase function (Fig. 2E). This novel 
mechanism underlying lipid overload-induced IR is depicted in (Fig. 2F). In conclusion, all 
tested hallmarks of lipid-induced IR in these cells are in close agreement with the described 
mechanism of lipid-induced IR (see Section 4), thereby establishing the suitability of these 
cells for cardiac IR-related studies. 
There are some limitations to the presented IR-model. In particular, the 30 days 
differentiated hESC-CMs do not fully represent the phenotype of the human adult 
cardiomyocyte. It has been pointed out that structural and functional maturity can be 
achieved by adjusted culture conditions (such as oxygen concentration)73, alternate 
medium composition (such as galactose and FA-rich medium)74, electrical stimulation75, and 
prolonged culture36-38,76. Furthermore, we used a 100 nM insulin concentration, as it is 
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known that cells in culture are less responsive to insulin stimulation than in vivo animal or 
ex vivo isolated heart models. Perhaps, further maturation of hESC-CMs may lead to a 
higher insulin response, as neonatal cardiomyocytes compared to adult, have high basal 
glucose uptake levels due to a relatively high GLUT1 expression, which makes them less 
responsive to insulin-stimulated glucose uptake77. Nevertheless, the 30 days-differentiated 
hESC-CMs show signs of metabolic differentiation and the ability to become insulin resistant 
thereby providing promising future outlook for the use of hESC-CMs as a model to study 
metabolic diseases. 
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7. Concluding remarks 
In summary, human in vitro cell models appear useful to obtain metabolic insight into 
human disease pathogenesis, especially in case of IR in the heart. On a large scale the 
molecular mechanisms in these human models seem to be mostly comparable to the 
currently used animal models, although it remains necessary to exclude whether 
fundamental differences, due to genetic, structural and physiological interspecies variation, 
are present. Currently, several human in vitro cell models are available, with hSC-CMs 
showing a good potential for application in future research. The ability to generate 
cardiomyocytes from human stem cells provides an unlimited source of cells without the 
need of invasive procedures. In our present study, we have developed a human in vitro 
model to study lipid-induced IR in human cardiomyocytes. We observed that upon 16 h HP 
treatment hESC-CMs acquire impairment in v-ATPase function and lose their sensitivity to 
insulin, suggesting that hallmark features of IR in the heart are conserved between rodents 
and humans. Although these 30 days differentiated cells might not fully display the 
cardiomyocyte-specific morphology and sarcomere organization43,78-80, their metabolic 
characteristics show a maturing metabolic phenotype as seen in the adult human heart. 
Therefore, HP treated hESC-CMs provide a promising, valuable human in vitro cell model to 
study cardiac IR. Moreover, functional measurements such as cardiac contractility and 
electrophysiological properties could be of additional value to confirm that the observed IR 
phenotype upon HP treatment also affects contractile function in this model. Finally, this 
model may be important for identifying novel therapeutic targets to combat T2D-induced 
heart failure. 
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Main findings of this thesis 
The aim of this thesis was to develop experimental models so as to enable the further study 
of molecular mechanisms underlying the development of pressure overload-induced heart 
failure and to explore the therapeutic potential of metabolic targeting. In this chapter, the 
most essential findings of this thesis are summarized and discussed in the context of 
currently available knowledge. In addition, an outlook towards future research and 
applications is provided. The main findings of this thesis are as follows:  
1. Stimulation of adult rat cardiomyocytes with phenylephrine (PE) for 24h provides 
an in vitro model that closely displays the main characteristics of pressure 
overload-induced heart failure (i.e. increased glucose uptake, increased protein 
synthesis, development of cardiac hypertrophy and contractile dysfunction). 
2. This PE in vitro model indicates that metabolic changes precede changes in protein 
synthesis and functional changes during the development of pressure overload-
induced heart failure.  
3. Metabolic targeting, in favor of decreased glucose utilization and/or increased 
fatty acid utilization, is beneficial for the pressure-overloaded heart. 
4. The induction of pressure overload in our young male Lewis rat model is 
accompanied by a relatively rapid development of severe heart failure and 
profound myocardial metabolic abnormalities which are more representative for 
end-stage heart failure than for early-stage heart failure.  
5. We developed a human in vitro model with embryonic stem cell-derived 
cardiomyocytes that is suitable to study lipid-induced insulin resistance.  
These main findings are further discussed in the following 3 sections. Findings 1 and 5 are 
summarized in the section “Models to study pressure overload-induced cardiac 
hypertrophy”, findings 2 and 4 in the section “Time course of metabolic, structural and 
functional changes during the development of pressure overload-induced heart failure”, 
and finding 3 in the section “Metabolic targets to rescue to pressure-overloaded heart”. 
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Models to study pressure overload-induced cardiac hypertrophy 
Dysfunctional energy metabolism plays an important role in the development of pressure 
overload-induced hypertrophy and heart failure. To study these metabolic impairments in 
relation to the development of heart failure, human cardiac biopsies can be obtained from 
patients. Unfortunately, however, these biopsies are often restricted to patients with end-
stage heart failure and/or derived after heart transplantation1. This limited access to patient 
and control tissue makes it difficult to study metabolic and structural changes over time 
during development. Nowadays, clinical studies therefore often/ideally focus on non-
invasive in vivo imaging (PET-imaging) of substrate metabolism in patients at different 
stages in the development of heart failure (i.e. hypertensive patients or patients with 
hypertension and left ventricular hypertrophy)2, 3. Such imaging forms a unique platform to 
identify metabolic changes in relation to cardiac structural and functional changes in 
patients before and during the development of pressure overload-induced cardiac 
hypertrophy and failure, and will open a new window for treatment strategies to prevent 
the development of heart failure. For further detailed investigation of the molecular 
mechanisms involved in the development of pressure overload-induced hypertrophy and 
failure, animal models are still desired.  
Animal models of pressure overload provide the great advantage to study the disease 
phenotype in a complex multicellular, interactive organ environment, which is not easily 
done in in vitro cell culture models. An ideal in vivo or in vitro model for cardiac pressure 
overload should accurately recapitulate the physiological and pathological conditions of the 
human heart. At the moment, the most widely used animal procedure to study the 
changes that occur during the development of pressure overload-induced heart failure in 
vivo is via constriction of the mid transverse aortic arch (TAC-surgery), by tightening a 
suture against a needle with a certain diameter4. Since this is a relative robust occlusion of 
the aortic arch this model closely represents the human disease phenotype of aortic 
stenosis. This method initially leads to the development of compensated cardiac 
hypertrophy, but it is suggested that this thickening of muscle wall eventually becomes 
maladaptive and results in cardiac dilatation and heart failure5. However, several 
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parameters, such as animal strain, age, sex, and needle size have been reported to affect 
study outcome6-8. Moreover, the degree of occlusion is highly operator-dependent and 
technically demanding, which may lead to considerable variation from study to study. 
Therefore, one must be careful when comparing results from different studies. To 
generate high precision and standardized degrees of aortic constriction, several new 
models have been developed, including transverse aortic constriction by the use of fixed 
diameter titanium clips and O-rings9, 10. In order to minimize variation in our study we 
choose to use the titanium clip approach to induce aortic constriction, as described in 
chapter 4. We specifically choose to use young rats (3 weeks of age) instead of adult rats, 
since it has previously been described that aortic banding in adult rats only leads to the 
development of compensated hypertrophy, whereas young rats do develop severe heart 
failure with decreased ejection fraction within a period of 15-20 weeks after TAC11. The 
fact that our results deviate from what has been described earlier by Doenst et al.12, even 
though the same protocol has been applied, may be explained by differences in rat 
strain13, i.e. Lewis versus Sprague-Dawley, respectively.  
Finally, one must take into account that the TAC-model, which resembles aortic stenosis, 
does not reflect the main characteristics of hypertension-induced pressure overload, 
which shows slowly progressing development of cardiac hypertrophy and finally failure. 
To study the gradual increase in pressure overload, less acute models are required. 
Widely used models in this perspective are the spontaneously hypertensive and dahl salt-
sensitive rats, which are often used to study compensated left ventricular hypertrophy and 
its transition to systolic heart failure14-17.   
In addition to the above-described in vivo models, animal-free in vitro studies with primary 
cells (adult or neonatal cardiomyocytes) or cell lines (rat ventricular H9c2 or mouse atrial 
HL-1 cells) provide an intriguing alternative. In vitro cell culture studies provide a valuable 
complement to in vivo experiments, allowing for a more controlled manipulation of cellular 
functions and processes, to study the underlying molecular mechanisms behind diseases 
and to relatively easy test pharmacological compounds. The benefit of immortalized cell 
lines is that they have the capacity to proliferate, whereas primary cardiomyocytes, which 
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are isolated directly from the hearts of rats or mice, have a finite lifespan (up to 
approximately 48h) and do not have any proliferation capacity18. When having a closer look 
into the metabolic properties of the various cardiomyocytes used to perform in vitro 
studies, it however appears that metabolic profiles differ tremendously between cell types. 
Whereas neonatal cardiomyocytes and the immortalized H9c2 cells and HL-1 cells are 
mainly dependent on glycolysis (similar to the fetal heart), primary adult cardiomyocytes 
are more dependent on fatty acid utilization, similar to the human adult heart19. This 
difference in metabolic properties among cells is important to keep in mind when metabolic 
alterations during the development of heart failure are the main focus of the study.  
To simulate pressure overload-induced cardiac hypertrophy in these cell models, an often-
used approach is cellular stimulation with hormonal activators/compounds such as 
endothelin-1 (ET-1), angiotensin-2 (AT-II), catecholamines and growth factors, which 
activate signaling pathways involved in cellular growth/hypertrophy20-24. Next to the well-
known release of ET-1 and AT-II from endothelial cells and kidney, respectively, chronic 
hypertension also leads to a local release of ET-1 and AT-II from cardiac tissue25-30. These 
locally available hormones trigger the activation of their G-protein coupled receptors 
(GPCRs), the endothelin receptor (ETA), and the angiotensin-1 receptor (AT-1)27, 31, thereby 
activating the hypertrophic program. Interestingly, in our study in chapter 3 we tested the 
above-mentioned stimuli, but did not observe an effect of ET-1 and Ang-II on hypertrophic 
gene expression (ANF and BNP) in adult rat cardiomyocytes. This might be related to 
contaminating factors in the collagenase buffer used during cell isolations, resulting in 
malfunctional receptor-ligand interactions. PE, on the other hand, was able to elicit a 
hypertrophic response, and therefore PE was used in our further studies. PE, is an α-1-
adrenergic receptor agonist, a pharmacological compound that mimics the effects of 
endogenous catecholamines (epinephrine, norepinephrine)32. Although this compound is 
non-physiologic it is able to activate several complex signaling molecules downstream of 
the protein kinase C pathway, thereby triggering a hypertrophic phenotype in 
cardiomyocytes and therefore a useful alternative to physiological compounds21, 33. It 
remains however important for understanding of the model to complement and properly 
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compare the findings of such in vitro models with more physiologic in vivo models of 
pressure overload. 
A new emerging model to study human heart failure is the human stem cell-derived 
cardiomyocyte. As described in chapter 5, human embryonic stem cell (hESC)- and human 
induced-pluripotent stem cell (hiPSC)- derived cardiomyocytes could provide the first step 
in the translation towards a human setting. So far, only few studies have focused on eliciting 
a hypertrophic response in hESC-derived cardiomyocytes, by showing increased cell size and 
increased hypertrophic gene expression after exposure to PE, ET-1, Ang-II, or mechanical 
stretch34-37. It remains, however, to be explored whether these current models are also able 
to display the main metabolic (i.e. increased glucose uptake) and functional characteristics 
(i.e. impaired contractile function) of pressure overload, since we (chapter 5) and others 
noted that the metabolic and structural properties of these stem cell-derived 
cardiomyocytes are currently not fully representative to the phenotype of the adult human 
heart38-40. Similar to rodent in vitro cell lines, stem cell-derived cardiomyocytes 
predominantly rely on glycolysis, rather than fatty acid utilization, thereby more closely 
representing a neonatal phenotype18, 41. Current research focusing on the improvement of 
metabolic, structural and functional maturation of this human cell model, forms a first step 
in the use of these cells to study cardiac diseases from a molecular perspective40, 42, 43. Once 
these improvements are realized, this human model would be a highly valuable tool to study 
pressure overload in a human setting.   
Overall, a perfect model to study pressure overload-induced heart failure does not yet exist, 
therefore it is currently still important to combine observations from both in vitro and in 
vivo animal models, and (if available) human models, to provide an accurate view on 
possible underlying mechanisms behind pressure overload-induced heart failure.   
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Time course of metabolic, structural and functional changes during the 
development of pressure overload-induced heart failure 
In this thesis we used several of the above mentioned models to study the underlying 
myocardial changes that occur during the development of pressure overload-induced heart 
failure. As described in the introduction of this thesis, chronic pressure overload, as a 
consequence of increased workload, induces cardiac hypertrophy and ultimately severe 
heart failure. It is well established that cardiac left ventricular hypertrophy and heart failure 
are associated with metabolic alterations (i.e. increased glycolysis for energy production)44, 
45, and it has been proposed that these metabolic changes form a trigger in the pathogenesis 
of the disease46, 47. However, the exact mechanism how these metabolic abnormalities 
relate to changes in protein synthesis, structure and function of the heart remains unknown.  
 
Metabolic changes during the development of cardiac hypertrophy  
In chapter 3, our in vitro model (i.e. PE-stimulated cardiomyocytes) showed increased 
cellular glucose and fatty acid uptake, increased protein synthesis, increased expression of 
hypertrophic markers and contractile dysfunction when compared to control cells. 
Moreover, we showed that metabolic changes in glucose and fatty uptake preceded 
changes in protein synthesis, expression of hypertrophic markers and contractile 
dysfunction. This indicates that metabolic changes precede structural and functional 
remodeling of the heart during the development of pressure overload-induced 
hypertrophy. This latter finding is supported by several in vivo studies12, 17, 48, 49. The studies 
in models of acute (TAC)48 and chronic (spontaneous hypertensive rats)17 pressure overload 
showed that glucose uptake was increased before changes in wall thickness and/or heart-
weight-to-body-weight-ratio were observed. In agreement with these animal studies, 
hypertensive patients showed higher myocardial glucose uptake rate compared to 
normotensive patients2. But surprisingly, hypertensive patients with cardiac hypertrophy 
showed reduced cardiac glucose uptake compared to hypertensive patients without cardiac 
hypertrophy2, which is not completely in line with the observations in the animal models, 
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where a clear increase in cardiac glucose uptake was noted during the progression towards 
cardiac hypertrophy16, 50. Despite these conflicting data, overall these results, combined 
with our own observations in chapter 3, suggest that exposure to both acute and chronic 
pressure overload, firstly triggers an increase in glucose uptake, which then contributes to 
the development of cardiac hypertrophy (structural remodeling of the heart). 
Some discripancy is observed for glucose oxidation in the pressure-overloaded heart. The 
increase in glucose uptake in hearts of spontaneous hypertensive rats, that were not yet 
hypertrophic, was paralled with an increase in glucose oxidation17, which remained 
prominent even at the hypertrophic stage17, 51, 52. But, these findings on increased glucose 
oxidation were not confirmed in sprague-dawley rats undergoing TAC surgery. In these rats 
hypertrophy developed within 2 weeks after TAC, but glucose oxidation was not yet altered 
at this time point12. The deviating results in terms of timing in alterations in glucose 
oxidation could perhaps be explained by the use of different models (systemic 
hypertension-induced versus aortic ‘stenosis’-induced) of pressure overload. In conclusion, 
whether glucose oxidation is already increased or unaltered at the early stage of pressure 
overload requires further investigation. 
The above described observations on glucose oxidation are different from what has been 
reported for fatty acid oxidation in the pressure-overloaded heart. Namely, fatty acid 
oxidation was already negatively affected at the early stage of compensated hypertrophy. 
Fifteen week-old spontaneous hypertensive rats showed reduced oleate oxidation53, and 
palmitate oxidation52, aortic banded rats 2 weeks after TAC a dramatic decline in fatty acid 
oxidation12, and dahl salt-sensitive rats a decline in β-oxidation metabolites50. These results 
show that impairment in fatty acid oxidation is already prominent at the early stage of 
compensated cardiac hypertrophy and precedes the development of severe heart failure. 
Our own data (chapter 3) support this idea of an early decrease in fatty acid oxidation, since 
ACC phosphorylation levels were decreased after 16h and 24h PE stimulation compared to 
control. This indicates that shuttling of fatty acids into the mitochondria, and thus most 
likely fatty acid oxidation, is already impaired in 16h PE-stimulated cells and thus before 
protein synthesis and cardiac function are affected (24h).  
Chapter 6  | 
134 
 
As described in detail in chapter 3, there is currently no clear consensus with respect to 
early changes in cellular fatty acid uptake in the pressure-overloaded heart. Our own data 
(chapter 3) which showed an early increase in fatty acid uptake after 16h PE stimulation 
(remaining to be present at 24h PE stimulation), is supported by two in vivo studies showing 
increased fatty acid uptake at the early stage of compensated hypertrophy50, 54. However, 
in animal models of acute and chronic pressure overload CD36 mRNA expression and total 
protein expression tend to be decreased (chapter 2), implying a decrease in fatty acid 
uptake. Therefore, perhaps the observed increase in fatty acid uptake is model related. 
However, it has to be noted that subcellular distribution of CD36 was not studied. 
Overall, the early stage of pressure overload is accompanied by an increase in glucose 
uptake, followed by reduced fatty acid oxidation and structural remodeling of the heart. 
Importantly, literature describing the metabolic changes at this early stage of pressure 
overload, especially changes in fatty acid uptake and in glucose oxidation, is contradictory 
and therefore would require more detailed investigation. 
 
Metabolic changes during the transition of compensated hypertrophy towards severe failure 
As heart failure progresses from compensated hypertrophy towards severe heart failure, 
the above described observations on increased glucose uptake at the early stage of pressure 
overload are no longer maintained. Towards the progression of severe heart failure glucose 
uptake was decreased in an animal model of pressure overload49, and a decrease in glucose 
uptake correlated with the severity of diastolic dysfunction in hypertensive patients2. The 
fact that we found no increase in glucose uptake in our rat model of pressure overload 
(chapter 4), points out that at 4 weeks after TAC these rats already encounter an advanced 
stage of heart failure in which the early increase in glucose uptake is no longer present.  
Interestingly, where there was either no effect or an increase in glucose oxidation observed 
at the early stage of pressure overload (2 weeks after TAC), a trend towards reduced glucose 
oxidation  was shown between 2 and 10 weeks after TAC, and a significant decline in glucose 
oxidation at 20 weeks after TAC12, 55. The unaltered ejection fraction in these rats until 10 
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weeks after TAC, and cardiac dilatation and impaired ejection fraction only present at 20 
weeks after TAC, together suggest that glucose oxidation is only decreased at a later stage, 
i.e., during the progression from compensated hypertrophy towards severe heart failure12, 
55.  
The decrease in glucose oxidation in rats with advanced stage of heart failure was 
accompanied by a decrease in fatty acid oxidation12, 55. This association with reduced fatty 
acid utilization in an advanced stage of heart failure has also been confirmed in human 
studies of patients with dilated cardiomyopathy (DCM)56-58. Beside these studies on fatty 
acid oxidation, an in vivo study in dahl salt-sensitive rats showed attenuated fatty acid 
uptake towards the development of severe heart failure50, which is further supported by 
our own model of advanced heart failure (chapter 4), showing a decline in fatty acid uptake.   
In conclusion, towards the development of severe heart failure, it seems that overall 
metabolism is affected. Both glucose uptake and oxidation, and fatty acid uptake and 
oxidation are declined compared to the early hypertrophic stage of heart failure.  
 
Protein synthesis and autophagy in the early and late stage of pressure overload-induced 
heart failure 
In addition to metabolic changes we looked at the underlying mechanisms explaining the 
observed structural changes in the pressure-overloaded heart. Cardiac hypertrophy is a 
dynamic process resulting from a disproportionate protein synthesis and protein 
breakdown. From other studies we know that the early increase in glucose uptake during 
the early development of pressure overload-induced cardiac hypertrophy is accompanied 
by the activation of mTOR47, 48, a well-known positive regulator of protein synthesis and 
cardiac hypertrophy. A similar pattern of increased glucose utilization and increased mTOR 
activity was observed in our in vitro model of PE-induced pressure overload already after 
16h PE stimulation, which was followed by enhanced protein synthesis and development of 
hypertrophy after 24h PE stimulation (chapter 3). In line with these results, indirect 
inhibition of mTOR, by Akt-I, was able to prevent the PE-induced increase in protein 
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synthesis (chapter 3). These results provide further evidence that the early activation of 
mTOR by pressure overload indeed plays an major role in the development of pressure 
overload-induced hypertrophy. This is also supported by studies in which mTOR activity was 
directly inhibited by rapamycin, resulting in a regression in cardiac hypertrophic response 
in the pressure-overloaded heart59-61. It is conceivable that the reduced glucose utilization 
at an advanced stage of pressure overload leads to the de-activation of mTOR, thereby 
shifting the protein turnover to favor protein breakdown, ultimately leading to ventricular 
dilation and the development of severe heart failure.  
Autophagy is one of the well-studied protein breakdown mechanisms in the pressure-
overloaded heart. In terms of autophagy at an early stage of pressure overload, there are 
however two contradictory hypotheses described in the literature: 1) Increased autophagy 
in the early stage of pressure overload as an essential mechanism to provide the heart with 
sufficient amounts of macronutrients, metabolites and organelles required for processes 
involved in ATP production (glycolysis and TCA cycle) and hypertrophic growth62, and 2) 
Reduced autophagic activity during the early stage of compensated hypertrophy, leading to 
protein turnover imbalance in favor of protein synthesis, thereby triggering the 
hypertrophic phenotype63. In our in vitro model (chapter 3), we did not observe any 
prominent early changes in autophagy response in PE-stimulated cells compared to control 
(16h and 24h). To draw clear conclusions with respect to autophagic activity in the early 
stage of pressure overload, time course studies, as performed to study metabolic 
alterations in the pressure-overloaded heart, could be of high value.   
Our in vivo model of advanced stage heart failure showed increased autophagic activity 
(chapter 4). This finding is in line with reported results on increased autophagy in animal 
studies during the progression from compensated hypertrophy towards severe heart failure 
and in hearts of patients with severe heart failure64-67. It has been proposed that, during the 
progression of compensated hypertrophy towards severe heart failure, an exuberant 
autophagic response is triggered by  endoplasmic reticulum (ER)-stress, due to 
accumulation of misfolded proteins that exceed the folding capacity of the ER47, 62. This 
increase in autophagy, together with the deteriorated energy status in the failing heart, 
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leads to excessive ROS production, degradation of non-specific essential metabolic enzymes 
and mitochondria, and thereby further impairment of both glucose and fatty acid 
metabolism and a further decline in ATP.  
Taken together, these data suggest that metabolic changes precede structural changes 
during the development of pressure overload-induced hypertrophy and failure. 
Additionally, these data provide evidence for a key role of mTOR towards the development 
of cardiac hypertrophy, and suggest that ER-stress might be an important factor in the 
transition from hypertrophy towards severe failure.  
 
Metabolic targets to rescue to pressure-overloaded heart 
The fact that metabolic changes precede structural and functional changes in the pressure-
overloaded heart, makes targeting metabolic abnormalities a promising therapeutic 
approach. Based on the above described results several metabolic interventions could be 
applied in the early prevention of pressure overload-induced heart failure: 1) Inhibition of 
glucose uptake, 2) Stimulation of glucose oxidation, 3) Stimulation of fatty acid uptake, 4) 
Enhancement of fatty acid oxidation. Chapter 3 of this thesis confirms that the use of 
compounds (Akt-I and DPY), that intervene in the metabolic substrate preference (via 
inhibition of glucose uptake and enhancement of fatty acid uptake), are protective in terms 
of maintaining contractile function in cardiomyocytes exposed to hypertrophic stimuli. This 
confirms that pharmacological intervention that target metabolic pathways, thereby aiming 
to restore the substrate balance in favor of fatty acid utilization (so as to obtain the 
metabolic profile as observed in the healthy adult heart) are indeed beneficial in terms of 
cardiac outcome.  
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Targeting glucose uptake 
Specific targeting of glucose uptake would be a valuable approach, given that glucose 
uptake is increased in the early stage of pressure overload. Compounds that inhibit glucose 
uptake could perhaps prevent the uncoupling between glycolysis and glucose oxidation as 
observed in the hypertrophic heart. We showed that specific inhibition of the 
Pi3k/Akt/mTOR pathway was protective in our in vitro study (chapter 3). This is most likely 
due to indirect inhibition of GLUT4 translocation to the sarcolemma, the main glucose 
transporter in the heart68. Interventions that specifically aim at inhibiting the GLUT4 
translocation machinery could protect the pressure-overloaded heart from developing 
hypertrophy and failure. The proteins that make up the GLUT4 translocation machinery are 
further detailed in the following references;69, 70. Expression of GLUT4 can also be regulated 
by targeting specific genes such as the hypertrophic transcription factor myocyte enhancer 
factor-2 (MEF2), which is upregulated in cardiac hypertrophy71. Additionally, targeting the 
increased expression of GLUT1 during pressure overload should not be forgotten. It has 
been reported that hypertrophy is accompanied by increased expression of HIF-1α72, 73 and 
activator protein 1 (AP1)74 and reduced levels of PPARα75, which are associated with 
increased expression of fetal-like-genes, such as GLUT1.  
Interestingly, we also observed increased activity of the PKD-pathway upon PE stimulation 
(chapter 3), which independently from the Pi3K/Akt/mTOR pathway is also involved in 
GLUT4 translocation. Whether this pathway plays an important role in pressure overload-
induced heart failure remains to be validated. PKD1 stimulates GLUT4 translocation via a 
yet unknown pathway involving endosomal lipid kinases76. Further unraveling the exact 
mechanism behind PKD1-activated GLUT4 translocation could lead to new strategies to 
combat pressure overload-induced heart failure.  
 
Targeting glucose oxidation 
Additionally, several studies have focused on enhancement of glucose oxidation as 
treatment of the pressure-overloaded heart, which (similar to inhibition of glucose uptake) 
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would promote a better coupling between glycolysis and glucose oxidation. Activation of 
pyruvate dehydrogenase (PDH), an enzyme involved in the conversion of pyruvate (the end-
product of glycolysis)  to acetyl-CoA, would achieve such a coupling and indeed appears to 
be beneficial in pressure overload-induced heart failure. Dichloroacetate (DCA) is a 
compound that inhibits the activity of pyruvate dehydrogenase kinase (PDK), thereby 
removing the inhibition of PDH and allowing the conversion of pyruvate to acetyl-CoA77. 
Treatment of dahl salt-sensitive rats with DCA prevented the progression of hypertrophy to 
heart failure and improved systolic cardiac function and survival16. However, studies in 
patients with congestive heart failure that were treated with DCA, reported some 
conflicting results. One study, with moderate and severe heart failure patients, found 
improved cardiac function after treatment with DCA78, whereas a subsequent study did not 
show any beneficial effects in patients with congestive heart failure79. Nevertheless, most 
studies point in the direction that enhancement of glucose oxidation in the pressure-
overloaded heart could ameliorate the development of cardiac hypertrophy and the 
progression towards severe heart failure. 
 
Targeting fatty acid uptake 
Although the exact role of fatty acid uptake in the pressure-overloaded heart remains to be 
investigated, targeting fatty acid uptake could be an additional promising approach. It was 
namely shown that cardiac-specific overexpression of CD36 (the predominant fatty acid 
transporter in the heart) protects the heart against pressure overload-induced heart 
failure80, which indicates that stimulation of fatty acid uptake (not only oxidation) is 
beneficial in the pressure-overloaded heart. This enhancement of cellular fatty acid uptake 
will increase the intracellular fatty acid pool, and will most likely force the heart towards 
fatty acid utilization. Targeting CD36 expression at the sarcolemma is therefore a 
considerable intervention option. This can for instance be achieved by targeting 
compartments of the trafficking machinery, which are specifically involved in CD36 
translocation from endosomal storage compartments to the cellular membrane70 or via the 
upregulation of genes involved in regulating fatty acid uptake, such as estrogen-related 
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receptor-α (ERRα)81, key peroxisome proliferator-activated receptor-α (PPARα), and its co-
activator PPAR-gamma co-activator-1α (PGC-1α)82. However, it should not be forgotten that 
a mismatch between fatty acid uptake and fatty acid oxidation could lead to the 
accumulation of lipid intermediates, thereby inducing lipotoxicity and insulin resistance in 
the heart. Hence, it should be checked, when targeting these trafficking proteins or 
transcription factors in the pressure-overloaded heart, whether the increase in fatty acid 
uptake would be accompanied by increased fatty acid oxidation. 
 
Targeting fatty acid oxidation 
This idea of restoring the metabolic profile, towards a profile as observed in the healthy 
adult heart, is supported by several in vivo studies focusing on enhanced fatty acid oxidation 
in the pressure-overloaded heart. PKD1-overexpressing mice, which are predominantly 
dependent on glucose utilization, developed cardiac hypertrophy and ventricular dilatation, 
but showed improved cardiac structure and function when subjected to a high-fat diet83. 
This high-fat diet generally leads to increased fatty acid oxidation. Additionally, mice with 
increased cardiac fatty acid oxidation, due to a cardiac-specific deletion of acetyl-CoA via 
acetyl-CoA carboxylase (ACC2), showed reduced glycolytic rates and anaplerosis, and were 
protected against the development of cardiac dysfunction induced by pressure overload 
(TAC and Angiotensin-2 infusion)84, 85. Moreover, diabetic mice and mice subjected to a high-
fat diet, showed less cardiac dysfunction after TAC surgery49, 80. These findings demonstrate 
that increased cardiac fatty acid utilization exerts cardio-protective effects after TAC. 
Screening for compounds that can enhance fatty acid oxidation, might be a useful future 
strategy to combat pressure overload-induced cardiac hypertrophy and ultimately failure.   
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Concluding remarks and future perspectives 
Pressure overload-induced heart failure is accompanied by metabolic changes, which most 
likely precede structural and functional changes in the heart. At the very early stage of 
pressure overload – before any structural remodeling occurs – the heart encounters an 
increase in glucose uptake, which is then followed by structural remodeling of the heart. 
This structural remodeling is accompanied by enhanced protein synthesis most likely driven 
by one of its key regulatory proteins, mTOR. The increase in glucose uptake is also followed 
by a decrease in fatty acid oxidation during the subsequent development of cardiac 
hypertrophy, and ultimately, as heart failure progresses towards severe failure, an overall 
decrease in substrate utilization (both glucose uptake and oxidation and fatty acid uptake 
and oxidation), leaving the heart with insufficient amounts of energy sources. 
Unfortunately, at the early stage of pressure overload there is no clear consensus regarding 
changes in fatty acid uptake and/or in glucose oxidation. Nevertheless, we can conclude 
that metabolic changes are pivotal during the (early) development and progression of 
pressure overload-induced heart failure. Future research should focus on mapping these 
metabolic changes in a time-dependent manner.  
Furthermore, unraveling the underlying mechanisms responsible for these changes in 
substrate metabolism will open a window for novel therapeutic targets that aim at restoring 
substrate metabolism in the failing heart. In order to obtain an overall picture with respect 
to the metabolic changes, it could be of significant value to combine and compare 
observations from different models (cell, animal and human models) in a longitudinal 
setting. However, it should be taken into account that models of acute pressure overload 
might differ from models of chronic pressure overload, and that animal models might not 
always reflect the pathophysiological situation in the human heart. Therefore, one should 
consider investigating all metabolic parameters within the same study to provide a coherent 
picture in specific models of pressure overload. Moreover, it should be kept in mind that 
timing is crucial for metabolic treatment in patients, due to the fact that there are different 
metabolic changes at different stages of heart failure. Ultimately, in vivo monitoring of 
substrate metabolism and of protein synthesis could allow for proper diagnosis and tailored 
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treatment of pressure overload-induced heart failure patients, including monitoring the 
efficacy of installed treatment.  
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The general aim of this thesis was to develop experimental models for pressure overload-
induced heart failure to enable the further study of the underlying molecular mechanisms 
contributing to the development of heart failure, as well as the study of various metabolic 
interventions to rescue the pressure-overloaded heart.  
Chapter 1 provides a general introduction on cardiac pressure overload and the 
contributing role of alterations in substrate metabolism and protein turnover in the 
development of pressure overload-induced heart failure. Additionally, the aim and the 
outline of this thesis have been described in greater detail.  
Chapter 2 highlights the current state of knowledge regarding substrate transporters (of 
both predominant and alternative substrates), and their key role in substrate utilization in 
the (pressure-overloaded) heart. Moreover, this chapter summarizes the main findings 
regarding expression levels and cellular distribution of these transporters in the pressure-
overloaded heart, and emphasizes their potency as therapeutic target to combat the 
development of cardiac hypertrophy and heart failure.  
Chapter 3 describes our developed in vitro cardiomyocyte model that closely mimics the 
main characteristics (increased glucose uptake, increased protein synthesis and expression 
of hypertrophic genes, and reduced contractile function) of pressure overload-induced 
cardiac hypertrophy. This model implies that metabolic changes occur before structural and 
functional changes in the pressure-overloaded heart. Moreover, this model will allow us in 
the future to (i) unravel the mechanisms behind this process in more detail, and to (ii) study 
whether metabolic interventions could prevent cardiac structural and functional changes. 
Our first metabolic interventions were aimed at decreasing glucose uptake. These 
interventions forced the cardiomyocytes to increase fatty acid utilization, resulting in 
restoration of contractile function, thereby supplying proof-of-concept that metabolic 
interventions can be used successfully to treat the hypertrophic heart. 
Chapter 4 describes metabolic changes in relation to changes in protein synthesis and 
cardiac function in an in vivo animal model of advanced stage pressure overload. Although 
the model was originally designed to study early-stage heart failure, alterations in cardiac 
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function and profound metabolic abnormalities where more representative for end-stage 
heart failure. Therefore, future research should focus on the refinement of this model 
towards a more slowly progressive model of pressure overload. 
Chapter 5 tested the hypothesis whether human stem cell-derived cardiomyocytes could 
function as a relevant human tool to study heart failure of metabolic origin. This chapter 
gives insight into the metabolic profile of human stem cell-derived cardiomyocytes and 
provides a novel cell line-derived in vitro model to study cardiac insulin resistance. Future 
research may focus on the implementation, of stem cell-derived cardiomyocytes in a model 
of pressure overload-induced heart failure, allowing us to make the translation of the 
findings presented in chapters 3 and 4 towards a human setting. 
Chapter 6, the general discussion, provides an overview on currently used models to study 
pressure overload-induced cardiac hypertrophy and failure. Moreover, our novel findings 
were discussed in more detail, an elaborated view on alterations in substrate uptake, 
oxidation and protein synthesis during the development of heart failure was given, and 
possible targets for metabolic intervention were highlighted.  
In conclusion, this thesis presents the importance of changes in substrate metabolism 
during the development of pressure overload-induced cardiac hypertrophy and heart 
failure. These findings extend the current knowledge on heart failure pathophysiology and 
may contribute to discovering new therapeutic targets.
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De algemene focus van dit proefschrift lag bij het ontwikkelen van experimentele modellen 
voor een type chronisch hartfalen waarbij de linkerventrikel van het hart een hogere druk 
moet genereren om bloed in de aorta te pompen (zoals aortaklepstenose en door hoge 
bloeddruk geïnduceerd hartfalen). Deze modellen stelde ons in staat om onderliggende 
mechanismen die ten grondslag liggen aan het ontstaan van deze vorm van hartfalen beter 
te kunnen bestuderen. Daarnaast zijn deze modellen gebruikt om verschillende metabole 
interventies te testen die gericht zijn op het voorkomen/behandelen van overdruk-
geïnduceerd hartfalen. 
De algemene introductie in hoofdstuk 1 gaat in op de rol van veranderingen in 
substraatmetabolisme en eiwitsynthese tijdens de ontwikkeling van overdruk-geïnduceerd 
hartfalen. Daarnaast worden de algemene doelstelling en de inhoud van deze thesis in 
detail beschreven.  
Hoofdstuk 2 gaat in op de huidige kennis met betrekking tot substraattransporters en hun 
functie in het substraatverbruik door het hart dat blootgesteld is aan overdruk. Daarnaast 
worden in dit hoofdstuk de voornaamste bevindingen met betrekking tot expressieniveaus 
en cellulaire distributie van deze transporters in het aan overdruk blootgestelde hart 
weergegeven. Tevens wordt nadruk gelegd op het feit dat deze transporters een potentieel 
therapeutisch target kunnen vormen in de strijd tegen hartfalen. 
Hoofdstuk 3 beschrijft ons ontwikkeld in vitro cardiomyocyte model waarin de voornaamste 
karakteristieken (toegenomen glucose opname, toegenomen eiwitsynthese en expressie 
van hypertrofie genen, en afgenomen  contractie functie) van overdruk-geïnduceerde 
cardiale hypertrofie worden weergegeven. Dit model impliceert dat metabole 
veranderingen vooraf gaan aan structurele en functionele veranderingen in het aan 
overdruk blootgestelde hart. Daarnaast zorgt dit model ervoor dat we in de toekomst (i) 
onderliggende mechanismen die ten grondslag liggen aan het ontstaan van hartfalen nader 
kunnen onderzoeken, en dat we (ii) metabole interventies kunnen testen die ons wellicht 
in staat stellen om cardiale structurele en functionele veranderingen tegen te gaan. Onze 
eerste metabole interventies waren gericht op het verlagen van de glucose-opname. Deze 
interventies forceerden cardiomyocyten om meer gebruik te maken van vetzuren als 
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substraat, wat resulteerde in een verbeterde contractiele functie. Deze resultaten 
bevestigen de hypothese dat metabole interventies nuttig kunnen zijn in het tegengaan 
en/of behandelen van cardiale hypertrofie. 
Hoofdstuk 4 beschrijft metabole veranderingen in relatie tot veranderingen in 
eiwitsynthese en cardiale functie in een in vivo diermodel met een gevorderd stadium van 
hartfalen. Hoewel het model aanvankelijk was opgezet om metabole veranderingen in het 
vroege stadium van hartfalen te bestuderen, pasten de waargenomen veranderingen in 
cardiale functie en in metabolisme meer bij een eindstadium van hartfalen. Verder 
onderzoek zal zich moeten richten op het verfijnen van dit model, dat wil zeggen naar een 
model waarbij de veranderingen ten gevolge van cardiale overdruk zich meer geleidelijk 
ontwikkelen. 
In Hoofdstuk 5 testten we de hypothese dat uit humane stamcel-gegenereerde 
cardiomyocyten kunnen fungeren als een relevant humaan in vitro model voor het 
bestuderen van hartfalen met metabole origine. Dit hoofdstuk geeft inzicht in de metabole 
profielen van stamcellen en stamcel-gegenereerde cardiomyocyten en introduceert een 
nieuw in vitro model voor het bestuderen van cardiale insulineresistentie. Toekomstig 
onderzoek zou zich moeten focussen op de implementatie van deze stamcel-gegenereerde 
cardiomyocyten in een model van overdruk-geïnduceerd hartfalen. Dit zou uiteindelijk 
kunnen bijdragen aan het vertalen van onze bevindingen (opgedaan in hoofdstuk 3 en 4) 
naar een humane setting. 
De algemene discussie in hoofdstuk 6 geeft een overzicht van de huidige modellen die 
gebruikt worden om overdruk-geïnduceerde hypertrofie en hartfalen te bestuderen. In dit 
hoofdstuk worden onze nieuwe bevindingen uitvoerig bediscussieerd en wordt een 
overzicht gegeven van veranderingen in substraatopname, substraatoxidatie en 
eiwitsynthese tijdens de ontwikkeling van hartfalen. Daarnaast worden potentiële 
metabole targets in meer detail besproken. 
Tot slot wordt in deze thesis het belang van veranderingen in substraatmetabolisme tijdens 
het ontwikkelen  van overdruk-geïnduceerde hypertrofie en hartfalen aangegeven. Deze 
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bevindingen vullen de huidige kennis met betrekking tot de pathofysiologie die ten 
grondslag ligt aan het ontstaan van hartfalen aan, en kunnen hierdoor bijdragen aan het 
vinden van nieuwe potentiële targets. 
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Socio-economic relevance and clinical potential 
Heart failure is the leading cause of death worldwide, currently affecting at least 26 million 
people 1, and continuously increasing in its incidence, prevalence, and economic costs 1. 
There are many external triggers that can lead to heart failure. Aortic stenosis and systemic 
arterial hypertension, each resulting in cardiac pressure overload, belong to the most-
frequent cardiovascular diseases and major risk factors of heart failure2. Currently, over 
1.13 billion people suffer from hypertension worldwide, a number that has nearly doubled 
since 1975 and is still on the rise3. Also the incidence of aortic stenosis, the most serious 
global valve disease problem, reaches epidemic proportions. With demographic aging of 
the global population the incidence of pressure overload-induced heart failure is expected 
to increase even further, thereby stressing the urgent need for effective medical therapy. 
Currently, there is, however, still no cure for pressure overload-induced heart failure, and 
unfortunately most available therapies are limited to symptom treatment. Before physical 
symptoms become apparent, the hearts of heart failure patients often already undergo 
asymptomatic structural and/or functional abnormalities (left ventricular dysfunction)4. 
Early detection and prevention are therefore of high importance. It has been proposed that 
derangements in cardiac energy substrate metabolism play a key role in the early 
pathogenesis of pressure overload-induced cardiac hypertrophy and eventually failure. 
Unravelling the underlying molecular triggers responsible for the occurring changes in 
substrate metabolism and protein synthesis, as seen in hypertrophying hearts, holds great 
promise to provide novel therapeutic strategies to prevent or treat the failing heart.  
 
Potential target groups 
The focus of this thesis is on the pathophysiology of heart failure  as a consequence of 
pressure overload. The content of this thesis holds relevant information for (1) academic 
scientists working in various research fields, including cellular biology and function, 
substrate metabolism, protein synthesis and cardiac (patho)physiology, (2) the 
pharmaceutical industry working on the development of drugs/therapies against pressure 
overload (hypertension and aortic stenosis)-induced heart failure, (3) 
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clinicians/cardiologists, (4) and patients with hypertension and/or aortic stenosis, who are 
at high risk of developing cardiac complications. Moreover, scientists working on diseases 
(or patients suffering from diseases), with similar metabolic derangements as observed in 
the pressure-overloaded heart, such as cancer, could ultimately also benefit from our new 
discoveries.   
 
To provide our obtained knowledge to the scientific community and beyond, our findings 
are published in scientific journals relevant to the research field, such as Cardiovascular 
Research, BBA-Molecular Basis of Disease and Journal of Biological Chemistry. Additionally, 
the studies described in this thesis were presented at relevant national (2nd Maastricht-
Nijmegen Science day, Nijmegen, The Netherlands; CARIM day 2016, Maastricht, The 
Netherlands; 17th Society for Heart and Vascular Metabolism conference, Amsterdam, The 
Netherlands) and international (14th Society for Heart and Vascular Metabolism conference, 
Beijing, China; 17th Dutch-German Joint Meeting of the Molecular Cardiology Working 
Groups, Göttingen, Germany) scientific meetings/conferences by means of oral and poster 
presentations.  
 
Activities and products 
The knowledge acquired in this thesis and the established in vitro and in vivo models to 
study pressure overload-induced heart failure, has provided our research group with new 
expertise and advanced understanding in the underlying molecular mechanisms 
contributing to the development of pressure overload-induced heart failure, allowing them 
and other scientists to use these models and this new knowledge to implement in future 
research.  
Additionally, products of great relevance for the society may be the public awareness of 
heart failure as a growing societal and economic burden. Connecting to cardiovascular 
foundations such as the Hartstichting and other health care organizations/professionals 
could make the knowledge described in this thesis better accessible and more useful for the 
benefit of the society. The main elements of public awareness campaigns by these 
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organizations, pay attention to signs and the sudden complications associated with heart 
failure, making the general public aware of heart failure symptoms and appropriate 
measures to take in case of an incident. Moreover, their patients education programs could 
help heart failure patients to make informed decisions and fully participate in all aspects of 
their illness, ultimately saving lives and enabling improved quality of live for patients with 
heart failure. Sharing information regarding research content and progress with these 
organizations, will not only allow these organizations to translate our findings to relevant 
information intelligible for layman, but will also allow foundations to assess whether 
funding in this particular research fields is needed.  
 
Innovation and future directions 
This thesis provides new insights into the metabolic changes during the development of 
pressure overload-induced heart failure. Continuing and expanding this research is highly 
essential if we aim to understand and further unravel the complex underlying mechanisms 
contributing to the development of cardiac hypertrophy and ultimately failure. In this thesis 
I provide evidence for the important role of changes in substrate metabolism during the 
development of pressure overload-induced heart failure. This fundamental research forms 
a first step towards the discovery of new potential therapeutic treatment targets. The facts 
that metabolic changes seem to precede structural and functional changes in the pressure-
overloaded heart, and the fact that metabolic interventions are able to protect 
cardiomyocytes from contractile dysfunction, provides new target sides for early and late 
stage metabolic intervention studies. Although we have established a useful in vitro model 
that closely mimics the main characteristics of pressure overload-induced cardiac 
hypertrophy, future research will have to confirm our in vitro findings in animal and 
ultimately human disease models. Despite the projects described in this thesis being mostly 
of fundamental nature, these findings provide the first “building blocks” for future 
implementation of metabolic substrate metabolism as a non-invasive diagnostic tool in 
hypertensive and aortic stenosis patients. In vivo monitoring of substrate metabolism in 
pressure overload-induced heart failure patients (including determination of the disease 
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stage) would provide a base for tailored and patient specific treatment. Moreover, future 
research should focus on screening for new compounds that might be able to restore 
metabolic abnormalities in the pressure-overloaded heart. 
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Daar is hij dan eindelijk, mijn eindresultaat na 4 jaar keihard werken. Ik ben dan ook 
ontzettend trots op het resultaat! Het was niet altijd even gemakkelijk, maar deze 4 jaar 
hebben mij laten inzien over hoeveel veerkracht en doorzettingsvermogen ik beschik. 
Tevens heb ik geleerd hoe belangrijk een sociale, stimulerende, en betrokken omgeving kan 
zijn. In dit hoofdstuk wil ik dan ook graag een aantal mensen bedanken, want zonder jullie 
steun, betrokkenheid en gezelligheid gedurende deze jaren was dit boekje nooit tot stand 
gekomen.  
Dank aan mijn promotieteam. Allereerst wil ik mijn promotor Jan bedanken voor het 
financieel mogelijk maken van mijn promotietraject. Bedankt voor de mogelijkheid die u mij 
heeft geboden om naar China te gaan. Mijn eerste SHVM ervaring maar zeker een congres 
en setting om niet snel meer te vergeten. Dank voor uw adviezen en final-touches aan 
posters, presentaties en publicaties en dank voor uw hulp met het formuleren van de 
stellingen.  
Mijn copromotoren Miranda en Joost. Miranda, dank voor je ondersteuning en feedback 
tijdens dit promotietraject. Ik bewonder je om jouw sterke drive en vermogen om altijd 
maar door te blijven gaan. Daarnaast zouden velen een voorbeeld mogen nemen aan je 
sociale en betrokken houding op de werkvloer, dank daarvoor. Succes met alles wat er in 
de toekomst op je pad gaat komen! Beste Joost, ondanks dat je hart en ziel bij vATPase en 
PKD ligt, wil ik je bedanken voor het delen van je kennis en je input tijdens mijn 
promotietraject.  
Dan mijn paranimfen, Francesco en Yvonne. Francesco, thanks for your interest and 
support during the last period of my PhD! I enjoyed your social interaction and our small 
scientific conversations. Lucky for me that you only live 4 streets away and that I can still 
stop by for your legendary tortellini nights or beers. I think I have tasted more beers in this 
last year then I ever did during my whole life, haha. I wish you all the best with your project, 
and you know where to find me if you need anything! Yvonne, het is fijn om op een dag als 
vandaag (en in de voorbereiding hierop) iemand naast je te hebben die precies weet wat er 
allemaal op je af gaat komen en iemand die over een brede wetenschappelijke kennis 
beschikt. Ik ben dan ook blij dat jij mijn paranimf wilt zijn! Ik bewonder je om je sterke 
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betrokkenheid naar anderen toe en waardeer je kritische en eerlijke visie op 
wetenschappelijk inhoud. Ik mocht samen met jou paranimf zijn tijdens de promotie van 
Jieyi, een hele leuke ervaring. Daarnaast wil ik je ook bedanken dat ik je altijd mocht 
benaderen voor protocollen en adviezen. Ook je hulp na mijn “fietsongevalletje” zal ik niet 
snel meer vergeten. Alle succes voor je eigen toekomst, waar die ook moge zijn!  
Thanks to the other former and current colleagues of the cardiac metabolism group. Will, 
jij was mijn rots in de branding gedurende de eerste 2 jaar van mijn AIO traject. De enige 
persoon die mij vooruit wilde helpen wanneer ik vast hing op de werkvloer. Meestal ging 
hier wel wat gemopper aan vooraf, maar heel stiekem mis ik die altijd zingende, strenge, 
betrokken, ervaren, franse radio-luisterende, lab expert wel. Agnieszka, jij werd onze 
nieuwe Will, haha! Dank voor je inzet met de proefdierstudie. Zonder jouw magische 
operatie-skills was deze pilot nooit van de grond gekomen. Dank voor je ondersteuning met 
isolaties in de laatste periode van mijn AIO-traject en dank voor je sociale interactie en 
luisterend oor. Yilin, Aomin, Shujin, Ozlenen, it was a great pleasure to meet you. Aomin 
and Shujin, good luck with finishing your thesis! Li-yen, Ms. Wong! Thank you for making 
this last period of my PhD full of social interaction. I really enjoyed our bike rides to Vaals, 
dinners, movie nights, drinks and other fun. Good luck with all your stem cell work! 
Vervolgens alle studenten die ik heb mogen begeleiden of waar ik mee heb mogen 
samenwerken gedurende deze 4 jaar. René, Daan, Akanksha, Huseyin, Tari en Amber. 
Bedankt voor jullie inzet en sociale interactie op de werkvloer! Amber en Tari, het was voor 
mij heel erg prettig om jullie als stagiaires binnen onze groep te hebben op het moment dat 
ik als “de Benjamin” binnen deze groep begon. Samen (met veel lol) bezig zijn op het lab en 
onze lunchmomentjes maakte het voor mij makkelijker om mijn weg te vinden in een groep 
waar ik vooral op mezelf aangewezen was. Amber, ik vind het super leuk dat we nog steeds 
contact hebben, drankjes en etentjes doen in de stad, en gezellig shoppen in Utrecht, 
Rotterdam of Maastricht (zolang de trein maar blijft rijden, haha). Dank voor je  luisterend 
oor de afgelopen jaren.  
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My roommate Jobran and our Italian expat Titiana. Thanks for making this last year of my 
PhD a period with a lot of social interaction and fun. Thanks for all the dinners, home 
cookings, parties, cinemas, game nights and tiramisu. 
The liver group, Dennis, Tulasi, LingLing, Inez, Albert, I wish you all the best with finishing 
your PhD. Ronit, not around that often, but always warm and friendly when we meet in the 
hallway. I am impressed with your ability to handle such a busy agenda. You are the power 
woman that many women wish to be! Willem, onze kennisboom van de afdeling, dank voor 
je altijd kritische blik en nuttige feedback tijdens lab meetings. Dank voor je openstaande 
deur om af en toe over bepaalde research topics te sparren. Tom, bedankt voor je luisterend 
oor en je adviezen/hulp wanneer ik daar behoefte aan had. Het was fijn om altijd bij jou en 
Yvonne aan te kunnen kloppen op het moment ik “ervaren hulp” nodig had. Ik wens je alle 
succes met jouw onderzoek. Al ben ik er van overtuigd dat jou dat allemaal wel gaat lukken!  
Marion en Petra, het was fijn om af en toe met jullie te lunchen en over alledaagse dingen 
te babbelen. Marion bedankt voor je input bij het schrijven van werkprotocollen en Petra 
bedankt voor al je hulp met papierrompslomp rondom de promotie etc.  
Daarnaast wil ik alle andere collega’s bedanken die in de loop van de jaren de MolGen 
afdeling zijn gepasseerd. Vivian en Patrick, alle twee al een tijdje niet meer werkzaam 
binnen deze afdeling, maar bedankt voor jullie adviezen m.b.t. celkweek en algemene lab 
zaken. Patrick, dank voor je hulp met het ontwerpen van primers. Vivian, bedankt voor je 
hulp en vele pogingen om met mij iets van het stamcel project te maken! Mike, Sofie en 
Karen, het was leuk om met jullie op dezelfde afdeling te werken. Jieyi, it was an honor and 
great pleasure to be your paranimf! 
Also many thanks to our collaborators in Jena, who kindly invited us to their lab to learn 
their TAC procedure in rats. Dr. Schwarzer (Michael), Christina and Estelle, it was a great 
pleasure to meet you all during several SHVM conferences and I really enjoyed our visit to 
Jena. Auch der Weihnachtsmarkt und das Weihnachtsfest mit Ihrem Labor. Vielen Dank! 
Daarnaast wil ik nog een aantal andere mensen binnen de universiteit van Maastricht 
bedanken. Ben, bedankt voor je hulp bij het interpreteren van mijn in vivo data. Het was 
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een genoegen om met jou als ervaren onderzoeker op het gebied van hartfalen te kunnen 
brainstormen. Florence, dank voor je adviezen tijdens het stamcel project. Dank aan de MF 
(Jacques, Peter, Helma en Nicole) voor ondersteuning met proefdieren binnen jullie 
faciliteit. Monika, it was very nice to work with you at our department and thanks for your 
advice and the good times! Gudrun en Patrick, bedankt voor jullie hulp met contractie 
metingen. 
Daarnaast is het fijn om familie en vrienden om je heen te hebben die je even uit de 
negatieve sleur van de onderzoekswereld halen en met jou genieten van alle andere dingen 
die de wereld, naast werk, nog meer te bieden heeft. Dank aan al mijn familieleden en 
vrienden voor het tonen van interesse. Hopelijk kan ik tijdens mijn verdediging ook jullie 
een beter inzicht geven in mijn onderzoek van de afgelopen 4 jaar. 
Cheryl, mijn wederhelft aan de andere kant van de wereld. Samen biomedische 
wetenschappen gestudeerd, alle twee op buitenland avontuur, alle twee terug voor ons 
promotietraject op de 5e verdieping in Maastricht, samen carnaval vieren, spelletjes 
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ook jullie bedankt voor de altijd gezellige avonden, etentjes, carnaval, etc. Mandy dank voor 
onze heerlijke stedentripjes naar Valencia en Athene tussen alle drukte op de werkvloer 
door. Ik zal die mega onweersbui in Valencia of jouw paella met slakken (i.p.v. de “goed 
doordachte veilige kip optie”) niet snel meer vergeten. Hahaha.  
Romboutsladies! Het is mooi om te zien dat, ondanks dat we ook allemaal onze eigen weg 
zijn gegaan, we nog steeds een vriendinnen groep zijn die graag samen lief en leed deelt. 
Bedankt voor onze jaarlijkse Oud en Nieuw, de 11e van de 11e, stap avondjes in Maastricht, 
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Garrix en nog veel meer. Met jullie valt altijd wel wat te beleven en ik hoop dat dit nog lang 
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hiervoor. 
Tot slot, familie Geraets. Lars bedankt voor het altijd beschikbaar stellen van je Jacuzzi! 
Heerlijk zo’n relax momentje tussendoor en dat in de achtertuin. Joey en Shirley, bedankt 
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